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The signal transducers and activators of transcription STAT3 and STAT1 share common 
structure and targets, but they play opposing roles in tumorigenesis. While STAT3 is considered 
an oncogene that promotes cell survival, proliferation, motility, and immune tolerance, STAT1 
enhances inflammation, favors cell cycle arrest, and apoptosis in most tumor cells. STAT3 has 
been found to be constitutively active in head and neck squamous cell carcinomas (HNSCC) 
where it promotes the cell cycle and prevents apoptosis, resulting in the proliferation and 
survival of HNSCC cells. We hypothesize that a small molecule inhibitor of STAT3 that is 
selective over STAT1 in HNSCC would serve as a powerful cancer therapeutic. The lead 
compound 669 that was identified through high content screening (HCS) displayed a pSTAT3 
inhibition with 10-fold greater selectivity over pSTAT1 in HNSCC cells (pSTAT3 IC50 5.50 ± 
1.50 μM (n = 7) vs. pSTAT1 > 50 μM). The mechanism of 669’s effect on the STAT3 pathway 
remains unknown, however, it does not proceed by a kinase inhibition pathway. This thesis 
describes the development of a structure activity relationship (SAR) for pSTAT3 inhibitors 
related to 669.  The key reaction to synthesize these analogs is performed in a microwave 
reactor, which saves time, and is convenient for parallel synthesis. 
Development of New Chemotherapeutics for Head & Neck Squamous Cell Carcinoma 
(HNSCC) 
Zhuzhu Wang, M.S. 
University of Pittsburgh, 2013
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1.0  INTRODUCTION AND BACKGROUND 
Head and neck squamous cell carcinoma (HNSCC) is the 6
th
 most common malignancy in the 
world with more than 500,000 new yearly cases and a 50% mortality rate.
1-3
 Risk factors for 
HNSCC include smoking, alcohol use, age, and HPV 16.
4,5
 HNSCC occurs in the areodigective 
tract, most commonly in the oral cavity, oropharynx, supraglottis, hypopharynx and glottis.
6,7
 
Typical symptoms are otalgia, dysphagia, dysphonia, and sore throat.
6,7
 Typical treatment 
regimens often combine radiotherapies with head and neck surgery which can significantly alter 
physical appearance.
8
 Current chemotherapeutics include cis-platin, methotrexate (MTX), 5-
Flurouracil, paclitaxel, and the monoclonal antibody (MAb) cetuximab (Erbitux®).
2,9,10
 These 
current treatments are not devoid of side effects and have very limited effects on overall survival 
rates.
1,2,9
 Thus, a new chemotherapeutic which would selectively target HNSCC cells would be 
very beneficial.    
Inhibition of the oncogenic signal transducer and activator of transcription (STAT3) is a 
potential strategy in treating this difficult cancer.
11,12
 On a molecular level, STAT3 serves as a 
transcription factor that affects cell differentiation, proliferation, apoptosis, angiogenesis, 
metastasis, and immune response.
13-16
 Elevated levels of constitutively activated STAT3 together 
with its increased transcription-regulated gene expression were found in most human cancers
13,16-
18
 which results in poor prognosis.
14,15,17,19
 In HNSCC cells, the level of inherently activated 
STAT3 is greater than that of normal epithelial cells.
20,21
 In HNSCC, the activated STAT3 
promotes tumor cell proliferation while preventing apoptosis.
13
 Treatment with dominant-
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negative STAT3 mutant transfection constructs or antisense STAT3 oligonucleotides results in 
tumor growth inhibition, apoptosis, and decreased STAT3 target gene expression.
20,22,23
 
In contrast to STAT3, STAT1 is anti-oncogenic. The STAT protein family has similar 
structural domains and common targets includes interferons (IFNs)
24-26
 / cytokines belonging to 
the gp130 family (such as interleukin (IL)-6
27
), growth factors such as platelet-derived growth 
factor receptor (PDGFR), and epidermal growth factor receptor (EGFR).
28
 In many tumor cell 
types, STAT1 serves to induce anti-proliferative and pro-apoptotic genes that directly arrest the 
cell cycle.
29-35
 In addition, STAT1 plays a key role in the inhibition of angiogenesis through 
acting on both endothelial and tumor cells.
36-38
 
1.1 STAT3 PROTEIN STRUCTURE 
STAT3 is one of the 7 members of the STAT family of proteins (the other six being STAT1, 
STAT2, STAT4, STAT5a, STAT5b and STAT6, which all serve in different cell signal 
pathways).
11,39
 STAT3 and STAT1 are the most studied of these proteins due to their opposite 
roles in tumorigenesis despite their structural similarities.
12,40
 STAT3 contains a N-terminal 
coiled-coil domain that is responsible for STAT dimer-dimer interactions, a DNA binding 
domain, a linker domain, a Src homology (SH2) domain, which is essential for the recruitment of 
STAT3 to the phosphorylated receptors followed by dimerization of activated STAT3 via 
phosphor-tyrosine (pTyr)-SH2 domain interaction, and a C-terminal transactivation domain.
11,41
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1.2 STAT3 SIGNALING PATHWAY 
In HNSCC, STAT3 is activated by both receptor and non-receptor tyrosine kinases via the 
tyrosine phosphorylation cascade. For the receptor tyrosine kinase, the transforming growth 
factor ((TGF)-α/EGFR) signaling activates STAT3 via the direct recruitment of the STAT3 SH2 
domains by the EGFR itself on its tyrosine residues, Y1068 and Y1086.
20,42
 The non-receptor 
tyrosine kinase constitutively associates with Janus kinase (Jak) proteins.
43,44
 Following the 
interleukin (IL)-6/gp130 interaction
45
 and aggregation of the receptor subunits, two associated 
Jak proteins promote tyrosine transphosphorylation, effecting reciprocal activation.
46,47
 These 
activated Jaks transmit cytokine signaling via recruitment and activation of STAT3 through the 
SH2 domain.
43,46,48-50
 Once recruited, STAT3 is activated by phosphorylation at Tyr705 by JAK 
or SRC. The activated STAT3 proteins undergo dimerization via the interaction between the 
pTyr705 and SH2 domain, respectively. STAT3 dimers then disassociate from the receptor and 
undergo nucleus translocation, where they bind to specific DNA sequences such as the cis-
element IFN-stimulated response element (ISRE) and regulate the transcription of target genes 
involved in cell cycle progression such as Fos, p21
WAF1/CIP2
, cyclins D1,
22,51-53
 D2, D3, CDC25A, 
APE1/Ref-1, c-Myc,
54-56
 and Pim1, or gene involved in angiogenesis such as VEGF,
57-59
 and 
anti-apoptosis genes including surviving,
60,61
 and Bcl-2, and Bcl-xL.
21,62
 
STAT3 inhibitors can be divided into two categories: peptides/peptidomimetics and small 
molecule non-peptidic inhibitors.
11,62
 These inhibitors can either indirectly block the targets (ex., 
interferons, cytokines) that are upstream of STAT3, tyrosine kinases such as JAK, SRC and 
EGFR that are crucial for STAT3 activation, or directly interact with STAT3 protein by targeting 
the SH2 domain, DNA binding domain, N-terminal domain which result in the either the 
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suppression of STAT3 phosphorylation, pSTAT3 dimerization, nuclear translocation, STAT3–
DNA binding, and expression of STAT3 target genes.
11,62
 
The first phosphopeptide inhibitor PY*LKTK (Y* represents pTyr) was designed based 
on the sequence of amino acids in the STAT3 SH2-binding region surrounding Tyr705 (1.1, 
Figure 1).
11,63,64
 The PY*LKTK peptide competitively binds to STAT3 which, effectively 
disrupts the pSTAT3-pSTAT3 dimerization and DNA binding activity, albeit at a DB50 of 235 
μM in Src-transformed NIH 3T3/v-Src fibroblasts (DB50 represents the concentration of peptide 
at which DNA binding activity is reduced by 50%).
63,64
 Additionally, the PY*LKTK exhibited a 
high selectivity for STAT3 over STAT5, but was only two-fold selective over STAT1.
64
 Further 
investigations have suggested that the tripeptide XY*L (Figure 1) contain the crucial sequence 
for the disruption of pSTAT3 dimerization and DNA binding. For example, the AY*L (1.2, 
Figure 1), and PY*L (1.3, Figure 1), disrupted STAT3 DNA binding, with nearly identical DB50 
values (DB50 = 217 μM and DB50 = 182 μM, respectively) as PY*LKTK but they do not inhibit 
STAT3-STAT1 or STA1-STAT1 dimers as effectively.
11,63
 The second phosphopeptide Ac-
Y*LPQTV-NH2 (1.4, Figure 1) was derived from the 904-909 amino acid residues of the STAT3 
receptor docking site on the gp130 subunit of the IL-6 receptor. Hexapeptide 1.4 was able to 
inhibit dimer formation and STAT3-DNA binding activity in vitro at sub-micromolar 
concentrations (IC50 = 0.15 μM), which represents a 133-fold improvement in inhibitory activity 
over the STAT3-derived peptide Ac-Y*LKTKF-NH2 (1.6, IC50 = 20 μM, Figure 1).
11,64-66
 
However, the biggest challenges of peptide inhibitors are their poor membrane permeabilities. 
Therefore, a hydrophobic membrane translocation sequence (mts) AAVLLPVLLAAP was 
attached to the C-terminus of the peptide to overcome this shortcoming. Cellular studies showed 
that the PY*LKTK-mts induced only 28% inhibition of STAT3 dimerization and DNA binding 
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activity, even at 1mM concentration.
11,63,64,66
 Whereas the Y*LPQTV-NH2-mts conjugate (1.5, 
Figure 1) was inactive.
11
 
 
Figure 1. Direct inhibition of STAT3: peptides 
 
Further peptidomimetics efforts based on tripeptides 1.2 and 1.3 have led to N-terminal 
structural modifications such as the replacement of pTyr-1 proline (or alanine) with 4-
cyanobenzoyl (ISS610 (1.7), Figure 2) that improved the inhibition of STAT3 dimerization and 
DNA binding activity (IC50 = 42 μM vs 182 μM (for PY*L) and 217 μM (for AY*L). Moreover, 
there was a significant increase in selectivity with IC50’s of STAT1-STAT1 and STAT5-STAT5 
dimers of 310 μM and 285 μM, respectively (as determined by electrophoretic mobility shift 
assay (EMSA) analysis).
64,66,67
 Docking studies suggested that the improved potency may be 
attributed to the 4-CN benzoyl moiety which occupies a hydrophobic pocket giving rise to 
additional interactions of the protein surface.
11,66
 The STAT3-DNA binding suppression of 
ISS610 has been demonstrated using mouse fibroblast cells (NIH3T3/v-Src), as well as human 
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breast tumor cells such as MDA-MB-231, MDA-MB-435 and MDA-MB-468, and lung 
carcinoma cells (A549).
11,66
 An additional peptidomimetic library derived from the ISS610 
through functionalization of the C-terminus has been developed.
11,66,68
 Unfortunately, all of these 
peptides were poor inhibitors of STAT3, but it is interesting to note that the m-methoxyaniline 
amide derivative ISS840 (1.8, Figure 2) exhibited a 20-fold preference toward STAT1 
homodimer inhibition (IC50 = 31 μM) compared with the STAT3 homodimer (IC50 = 560 μM), 
possibly due to additional hydrophobic contacts with Y603 and I616.
11,66
 
 
Figure 2: Direct inhibitors: peptidomimetics 
 
Small molecules constitute the largest class of nonpeptide STAT3 inhibitors with 
numerous methods to identify possible molecular candidates including high-throughput 
screening (HTS) of large chemical libraries, virtual screening, rational design based on peptides 
and peptidomimetic inhibitors, fragment-based drug design, and drug repositioning using 
multiple ligand simultaneous docking (MLSD).
62
 
STA-21 (1.9, Figure 3) was discovered to inhibit STAT3-dependent luciferase activity in 
breast and ovarian cancer cell lines through virtual screening.
69
 It was 5-fold more potent than 
the untreated controls (at 20 μM) in inhibiting luciferase activity of the MDA-MB-435s cells that 
were stably transfected with a STAT3-dependent luciferase reporter pLucTKS3.
62,69
 STA-21 also 
inhibited STAT3 dimerization, nuclear translocation, and STAT3-DNA binding activity in 
MDA-MB-435s cells at 20 or 30 μM.62,69 In addition, STA-21 inhibited the STAT3-regulated 
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downstream regulator Bcl-XL and cyclin D1 in MDA-MB-468 cells, but did not affect the 
phosphorylation of STAT3 upstream regulators JAC2 (P-JACK2), Src (P-Src), and the EGFR 
receptor (P-EGFR). This observation suggests that STA-21 is a direct inhibitor at the STAT3 
protein level.
69
 
Several more potent STA-21 analogs like LLL-12 (1.10, Figure 3) have recently been 
reported
11,62
 and represent an emerging class of selective small molecule STAT3 inhibitors with 
improved drug like properties.
62,70
 Using breast cancer MDA-MB-231-cloned cells that stably 
integrate the STAT3-dependent luciferase reporter pLucTKS3, LLL-12 inhibited luciferase 
activity by 10-fold (at 5 μM) compared to untreated controls.70 Furthermore, LLL-12 not only 
inhibited STAT3 activation at 5-10 μM in six cancer cell lines (MDA-MB-231 and SK-BR-3 
(breast), HPAC and PANC-1 (pancreatic), U87 and U373 (glioblastoma)) that express elevated 
levels of STAT3 phosphorylation but also inhibited STAT3 phosphorylation induced by IL-6 in 
MDA-MB-453 cells in a dose dependent manner.
70
 The inhibition of STAT3 DNA binding and 
transcription of STAT3-regulated gene was observed with LLL-12 at 10 μM. In addition, LLL-
12 suppressed tumor growth in mouse xenograft models of breast cancer and glioblastoma with 
daily intraperitoneal dosage of 2.5 to 5 mg/kg.
70
 
 
Figure 3: STA-21 and its analog 
 
S31-201 (1.11, Figure 4) was also discovered through structure-based virtual screening
71
 
where the salicylic acid moiety was incorporated as the phosphate mimetic.
66,72
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extract of EGF-stimulated mouse fibroblasts NIH 3T3/hEGFR, S31-201 preferentially inhibited 
the DNA binding ability of STAT3-STAT3 dimer (IC50 = 86 μM) compared to STAT1-STAT3 
dimers (IC50 = 160 μM) and STAT1-STAT1 dimers (IC50 > 300 μM).
62,71
 In the normal mouse 
fibroblasts (NIH 3T3) that were transiently cotransfected with the STAT3-dependent luciferase 
reporter pLucTKS3, S31-201 significantly inhibited the luciferase signal in a dose-dependent 
manner.
71
 S31-201 also induced apoptosis of malignant cells harboring constitutively active 
STAT3 (ex: MDA-MB-435), where they repressed the expression of the STAT3-regulated genes 
encoding cyclin D1, Bcl-xL, and survivin.
71
 S31-201 also suppressed tumor growth in mouse 
xenograft models of hepatocellular carcinoma and breast cancer.
62,71,73
 
 
Figure 4: S31-201 
 
Stattic (1.12, Figure 5) was identified as a STAT3 SH2 domain inhibitor via high-
throughput screening of a diverse chemical library using a fluorescence polarization-based 
binding assay.
74
 This compound inhibited the binding of STAT3 SH2 domain and the 
phosphotyrosine-containing peptide on the gp130 receptor with a IC50 of 5.1 μM at the 
physiologically relevant temperature of 37°C.
62,74
 It also inhibited STAT3 DNA binding at 10 
μM in the EMSA performed at 37 °C while the binding of STAT1 DNA was not significantly 
effected at concentrations up to 200 μM in the nuclear extracts from EGF-stimulated cells.62,74 
Stattic selectively inhibited IL-6 induced phosphorylation of STAT3 at Tyr705 in HepG2 liver 
carcinoma cells (20 μM), without interfering with the IFN- γ induced activation of STAT1 at 
Tyr701.
74
 However, it showed equipotent activities against phosphorylation of STAT3 and 
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STAT1 induced by IL-6 or leukemia inhibitory factor (LIF) in human ovarian cancer OVZAR-8 
cells at 5 or 10 μM.62 
 
Figure 5: Stattic 
 
Curcumin (1.13, Figure 6) also has been shown to inhibit IL-6-induced STAT3 
phosphorylation and nuclear translocation.
62,75
 The related analogs FLLL11 (1.14, Figure 6) and 
FLLL12 (1.15, Figure 6) are more effective than curcumin at inhibiting STAT3 phosphorylation 
and inducing apoptosis in pancreatic cancer cell lines in a dose-dependent manner.
62,75
 FLLL12 
was the most potent (10 μM) of these three compounds in pSTAT3 inhibition, STAT3-DNA 
binding, and transcriptional activity in breast and prostate cancer cells.
62,76
 Another analog, 
FLLL32 (1.16, Figure 6) down-regulated STAT3 phosphorylation, DNA binding, and the 
expression of STAT3 target genes at 10 μM in MDA-MB-231 and PANC1 cells77 and inhibited 
JAK2 kinase activity (IC50 = 5 μM). A series of in vivo studies showed that the administration of 
FLLL32 significantly inhibited tumor growth and vascularity in chicken embryo xenografts and 
reduced tumor volumes in mouse xenografts.
77
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Figure 6: Curcumin and its analogs 
1.3 STAT3 INHIBITORS IN CLINICAL TRIALS 
At present, there are no approved STAT3 inhibitors, but there are several promising compounds 
currently under investigation in clinical trials for treatment of advanced tumors and cancers.
62
 
The double-stranded oligodeoxynucleotide (dsODN) is the only drug candidate that has 
completed a phase 0 pharmacodynamic clinical study to evaluate the safety and biological effects 
of intratumoral injection in HNSCC patients.
17,78
 dsODN decreased the tumoral expression of 
STAT3 target genes following a single intralesional injection, but its rapid degradation in serum 
prevents systemic administration. Chemical modification of the decoy may be able to improve 
metabolic stability, which would allow for alternative means of delivery. However, these 
modified dsODNs would introduce additional significant pharmacokinetic challenges.
17
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2.0  THE STAT3 INHIBITOR 669 
Previous studies in our center have identified 669 (Figure 7) as a lead compound that selectively 
targets STAT3 over STAT1 in CAL33 cells with an IC50 = 5.50 ± 1.50 μM (n = 7) for pSTAT3 
versus an IC50 > 50 μM for pSTAT1 (Table 1). The IC50 values were assessed by measuring the 
concentration of 669 at which the translocation of pSTAT3-pSTAT3 dimers into the nucleus is 
reduced by 50% in CAL33 cells upon the initial pSTAT3 induction using interleukin-6 (IL-6). 
The net effect of the compound treatment would be a reduction of active STAT3-STAT3 dimers 
available to bind DNA. These values were measured from the high content screening (HCS) of 
97,000 compounds from the MLSCN (molecular library screening center network), which was 
performed by Dr. Paul Johnston and based upon an assay by Dr. Jennifer Grandis. Additional 
HNSCC cellular growth inhibition studies of 669 from Dr. Johnston’s lab indicated IC50 values 
of less than 10 μM (e.g., CAL-33, 686 LN, FADU, OSC) (Table 1). Kinase-profiling studies 
(Millipore UK) indicated that 669 only weakly inhibited six of the 83 tested kinases (20-40% at 9 
μM), suggesting that 669 is neither a potent nor promiscuous kinase inhibitor, but rather a direct 
inhibitor of the STAT3 pathway. 
 
 
  12 
 
Figure 7: Structure of lead compound 669 
 
Table 1. Properties of lead compounds 669 
 SID-864669 
HCS STAT3 IC50 (μM) 5.50 ± 1.5 (n = 7) 
HCS STAT1 IC50 (μM) > 50 (n = 7) 
Luciferase (% decrease, 8h) 30 
GI CAL-33 IC50 (μM) 9 
GI 686 LN IC50 (μM) 8.7 
GI FADU IC50 (μM) 4.6 
GI OSC IC50 (μM) 5.2 
FP binding assay @50 μM (% inhibition) < 10 
Western blot: Cyclin D1 + 
Western blot: Bcl-XL + 
MW 391.3 
cLogP 3.17 
Ligand efficiency (LE) 0.31 
Ligand-lipophilicity efficiency (LLE) 2.57 
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3.0  SYNTHESIS OF 669 ANALOGS 
3.1 SPECIFIC AIM 1 
Our first specific aim was to attain an inhibitor with a high selectivity and potency for targeting 
pSTAT3 over pSTAT1 in order to develop a HNSCC drug with a good safety and efficacy 
profile. To fulfill this goal, a series of 669 analogs was prepared. We maintained the 
triazolothiadiazine substituted pyrazole scaffold and focused on substitutions and ring sizes at the 
R1 and R2 positions (Figure 8).  
 
Figure 8. 669 Matrix library 
N
N
N
N
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N NC
Cl
Cl
Cl
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The procedure to synthesize the key triazolothiadiazine moiety involved a microwave-
assisted cyclodehydration similar to a Hantzsch thiazole synthesis (Scheme 1).
79
  
 
Scheme 1. Synthesis strategy of 669 analogs 
 
The α-chloro (bromo) ketone reagents were either commercially available, or synthesized 
in very good yields via a one-step addition of 2-chloroacetyl chloride. (Scheme 2).
80,81
 
 
Scheme 2. Synthesis of 2-chloro-1-(1H-indole-3-yl)ethan-1-one and 2-chloro-1-(5-chlororhiophen-2-yl)ethan-
1-one 
 
The pivotal triazole intermediates were not commercially available, but were synthesized 
following literature protocols (Scheme 3).
82,83
 Cyclopentanone was treated with diethyloxalate 
for 7 h in the presence of freshly made sodium ethoxide solution to afford ethyl 2-oxo-2-(2-
oxocyclopentyl)acetate (3.1) in 76% yield (Scheme 3). The subsequent cyclodehydration of the 
1,3-diketone with hydrazine hydrate in acetic acid afforded the cyclopentapyrazole (3.2) in 37% 
yield, which was then converted to the primary amine (3.3) after treatment with hydrazine 
hydrate in absolute ethanol. The amine (3.3) was converted to the potassium salt (3.4) in 
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quantitative yield after 16 h treatment with CS2. The product was immediately subjected to ring 
closure to form the 4-amino-5-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4H-1,2,4-triazole-3-
thiol (3.5) after 2 h reflux in absolute ethanol in the presence of hydrazine hydrate. 
 
Scheme 3. Synthesis of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
 
According to the cyclization condition depicted in Scheme 1, a total of fifty-six 669 
analogs were synthesized and their structures are listed in Table 2. 
 
Table 2. pSTAT3 inhibitors of 669 analogs 
 
Compd R1 R2 Yield 
(%) 
Compd R1 R2 Yield 
(%) 
3.6 3,4-Cl-Ph -C3H6- 88 3.34 3,4-Cl-Ph Ph 65 
3.7 4-OMe-Ph -C3H6- 78 3.35 3-Cl-Ph Ph 74 
3.8 2-Cl-Thiophen-
5-yl 
-C3H6- 54 3.36 4-Cl-Ph Ph 82 
3.9 3-Cl-Ph -C3H6- 40 3.37 4-F-Ph Ph 46 
O
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3.10 4-Cl-Ph -C3H6- 43 3.38 Ph Ph 74 
3.11 4-CN-Ph -C3H6- 56 3.39 Indol-3-yl Ph 69 
3.12 Pyridine-4-yl -C3H6- 63 3.40 4-CN-Ph Ph 67 
3.13 t-Bu -C3H6- 61 3.41 2-Cl-Thiophen-
5-yl 
Ph 77 
3.14 H -C3H6- 24 3.42 Pyridin-4-yl Ph 72 
3.15 4-F-Ph -C3H6- 50 3.43 H Ph 68 
3.16 Ph -C3H6- 70 3.44 Me Ph 90 
3.17 Indol-3-yl -C3H6- 67 3.45 2-Cl-Ph Ph 74 
3.18 Me -C3H6- 61 3.46 t-Bu Ph 90 
3.19 Hexanyl -C3H6- 83 3.47 4-OMe-Ph Ph 67 
3.20 3,4-Cl-Ph -C4H8- 92 3.48 Hexanyl Ph 79 
3.21 4-OMe-Ph -C4H8- 97 3.49 3,4-Cl-Ph 4-F-Ph 72 
3.22 2-Cl-Thiophen-
5-yl 
-C4H8- 80 3.50 4-Cl-Ph 4-F-Ph 55 
3.23 3-Cl-Ph -C4H8- 49 3.51 4-F-Ph 4-F-Ph 57 
3.24 4-Cl-Ph -C4H8- 70 3.52 4-OMe-Ph 4-F-Ph 60 
3.25 4-F-Ph -C4H8- 72 3.53 4-CN-Ph 4-F-Ph 39 
3.26 Indol-3-yl -C4H8- 60 3.54 t-Bu 4-F-Ph 83 
3.27 4-CN-Ph -C4H8- 73 3.55 Me 4-F-Ph 32 
3.28 Pyridin-4-yl -C4H8- 50 3.56 Ph 4-F-Ph 69 
3.29 t-Bu -C4H8- 52 3.57 2-Cl-Thiophen-
5-yl 
4-F-Ph 59 
3.30 H -C4H8- 43 3.58 3,4-Cl-Ph 4-Cl-Ph 69 
3.31 Me -C4H8- 89 3.59 4-CN-Ph 4-Cl-Ph 
63 
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3.32 Ph -C4H8- 90 3.60 Ph 4-Cl-Ph 
84 
3.33 2-Cl-Ph -C4H8- 89 3.61 2-Cl-Ph 4-Cl-Ph 
64 
 
However, attempts to prepare the 2,6-Cl-Ph at the R1 position were not successful 
(Scheme 4). The cyclodehydration of the ketone on the 2-bromo-1-(2,6-dichlorophenyl)ethanone 
was inefficient. Treatment with Cs2CO3 and tetrabutylammonium iodide (TBAI) also did not 
facilitate the cyclodehydration, as both reactions afforded the acyclic intermediates in very low 
isolated yield. Ultimately, these analogs had no inhibitory pSTAT3 activities.  
 
Scheme 4. Attempts at substituting a 2,6-Cl-Ph analog at the R1 position 
3.2 SPECIFIC AIM 2 
The ADMET properties of 669 including the in vitro clearance have been evaluated at the NCI 
using human and mouse microsomes. Unfortunately, the half-lives of the compound 669 in 
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human microsomes are 14 and 4.4 min, respectively. The metabolites of 669 in mouse 
microsomes have been analyzed and a major oxidation product (M+16) was observed, 
presumably occurring via a phase I metabolic process, which could be the result of S-
dealkylation, S-oxidation, or oxidation of the arene.  
Initial attempts to improve metabolism were realized through the preparation of a second 
library of 669 analogs where the α-position to the sulfur was substituted with a methyl group. 
The synthetic strategy is demonstrated in Scheme 5, and the original α-chloro (bromo) ketone 
was replaced by the α-methyl, α-chloro (bromo) ketone for incorporation of the desired methyl 
substituent. 
 
Scheme 5. Synthetic strategy of SOM blocked 669 analogs 
 
The α-methyl, α-chloro (bromo) ketones were either commercially available or 
synthesized via one-step α-bromination of the corresponding ketone precursors. For example, the 
2-bromo-1-(4-methyoxyphenyl)propan-1-one (3.62) was obtained by treatment of 4-
methoxypropiophenone with Br2 in dry diethyl ether and the 2-bromo-1-(3,4-
dichlorophenyl)propan-1-one (3.63) obtained in high yield using analogous conditions (Scheme 
6).
84
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Scheme 6. Synthesis of 2-bromo-1-(4-methoxyphenyl)propan-1-one and 2-bromo-1-(3,4-
dichlorophenyl)propan-1-one 
 
The second generation library of 669 analogs (11 compounds) that contain the α-methyl 
group at a potential site of metabolism is tabulated in Table 3. 
 
Table 3. SOM blocked pSTAT3 inhibitors of 669 analogs 
 
Compd R1 R2 Yield (%) Compd R1 R2 Yield (%) 
3.64 4-OMe-Ph -C3H6- 93 3.70 Ph 4-F-Ph 95 
3.65 3,4-Cl-Ph -C3H6- 71 3.71 4-OMe-Ph 4-F-Ph 84 
3.66 Ph -C3H6- 77 3.72 4-OMe-Ph 4-Cl-Ph 72 
3.67 4-Cl-Ph -C3H6- 28 3.73 Ph 4-Cl-Ph 84 
3.68 4-F-Ph -C3H6- 60 3.74 Ph Ph 93 
3.69 Ph -C4H8- 91     
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O
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96%
O
Br
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93%
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Cl Cl
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However, attempts to prepare the gem-dimethyl substitution at the α-position directly 
from the unsubstituted precursor were unsuccessful (Scheme 7). The use LDA (2 eq.) and MeI (3 
eq.) resulted in an unidentified compound. 
 
Scheme 7. Attempt at preparing a gem-dimethyl substitution 
 
As an alternative, we wanted to protect the pyrazole before attempting additional 
deprotonation and alkylations. However, the protection of pyrazole amine was unsuccessful 
under a variety of conditions (Table 4). The reaction did not proceed upon treatment with TBSCl 
and imidazole in THF even when warmed to 60 °C (Table 4, entry 1-2). Microwave assisted 
heating at 100 °C also did not facilitate this reaction (Table 4, entry 3). The use of strong base 
only resulted in unidentifiable products (Table 4, entry 4-6).  
 
Table 4. Attempts to protect the pyrazole 
 
Entry Conditions Results 
1 TBSCl, imidazole, 0 °C to rt, THF No reaction 
2 TBSCl, imidazole, 60 °C, THF No reaction 
3 TBSCl, imidazole, MW, 100 °C, THF No reaction 
N
N
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N
N
N
NH
2 eq LDA
3 eq MeI
THF
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N
N
N
NH
N
N
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N
N
N
NH
Conditions N
N
S
N
N
N
N
PG
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4 n-BuLi, TIPSCl, THF/DMF, -78 °C Unidentified material 
5 HMDS, (NH4)2SO4, 80 °C Unidentified material 
6 NaH, TIPSCl, DMF, 0 °C to rt Incorrect mass by LCMS 
 
We then decided to use the cyclodehydration conditions for the corresponding α-halo 
intermediate (Scheme 8). Upon treatment of the 4-amino-5-(1,4,5,6-
tetrahydrocyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-3-thiol with 2-bromoisobutyrophenone at 
95 °C in a microwave for 150 min, followed by 120 °C for 30 min, the desired product (3.75) 
was obtained in 7% yield.  
 
Scheme 8. MW-assisted 669 analog synthesis 
 
The use of Et3N as an additive provided the desired gem-dimethyl analog (3.75) in 41% 
yield after 8 h at 80 °C in EtOH (Scheme 9).
85
 
 
Scheme 9. Synthesis of geminal methyl substituted 669 analog 
  
Subsequent reactions using microwave conditions in the presence of Et3N afforded the 
desired product in higher yield (Scheme 10). The addition of 3 eq of Et3N, 4-Amino-5-(5-(4-
chloro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol and 2-bromoisobutyrophenone 
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afforded the desired product (3.76) in 63% yield after 1 h heating in the microwave at 95 °C in 
EtOH.  
 
Scheme 10. Microwave assisted 669 analog synthesis in the presence of Et3N 
 
The gem-dimethyl substituted 669 analog has also been prepared (Scheme 11). 
Commercially available 3,4-dichlorobenzoyl chloride was converted to the Weinreb amide (3.77) 
in 96% yield,
86
 which was then converted to the corresponding ketone (3.78) upon treatment 
with 1 eq of isopropylmagnesium chloride.
87
 Bromination at the α position of the ketone was 
achieved by the treatment of phenyltrimethylammonium tribromide in THF at room temperature, 
and afforded the desired precursor (3.79) in 85% yield. Finally, cyclodehydration in the presence 
of 3 eq of Et3N afforded the desired analog (3.80) in 67% yield. 
 
Scheme 11. Synthesis of compound 3.80 
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Other analogs have also been synthesized with larger groups such as Ph, iso-Pr, Bn, and 
iso-butyl blocking the position alpha to the sulfur (Table 5).  
 
Table 5. SOM blocked pSTAT3 inhibitors of 669 analogs 
 
Compd R1 R2 R3 Yield (%) 
3.81 Ph -C3H6- Ph 42 
3.82 3,4-Cl-Ph -C3H6- i-Pr 62 
3.83 4-OMe-Ph -C3H6- i-Pr 61 
3.84 4-OMe-Ph Ph i-Pr 59 
3.85 3,4-Cl-Ph -C3H6- Bn 64 
3.86 4-OMe-Ph -C3H6- Bn 82 
3.87 3,4-Cl-Ph Ph Bn 88 
3.88 4-OMe-Ph Ph Bn 94 
3.89 3,4-Cl-Ph Ph i-Bu 81 
3.90 4-OMe-Ph Ph i-Bu 87 
3.91 3,4-Cl-Ph -C3H6- i-Bu 66 
3.92 4-OMe-Ph -C3H6- i-Bu 65 
 
The requisite ketones for this series were not commercially available, but were readily 
prepared from the Weinreb amide and the corresponding Grignard reagent followed by 
bromination. (Scheme 12).  
N
N
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Scheme 12. Synthesis of brominated precursor ketones 
3.3 SPECIFIC AIM 3 
In order to investigate the importance of the pyrazole present in the 669 series, the n-propyl, Bn, 
iso-propyl, and Ph containing analogs were prepared using the standard microwave mediated 
cyclization conditions (Table 6). 
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Table 6. 669 Analogs lacking the 1,2-pyrazole 
 
Compd R1 R4 Yield (%) 
3.100 4-OMe-Ph n-propyl 78 
3.101 4-OMe-Ph Bn 67 
3.102 4-OMe-Ph iso-propyl 85 
3.103 4-OMe-Ph Ph 81 
3.104 3,4-Cl-Ph Bn 91 
N
N
S
N
N
R1
R4
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4.0  BIOLOGICAL RESULTS AND DISCUSSION 
All the synthesized 669 analogs were evaluated for their inhibitory activity against pSTAT3 and 
pSTAT1 in CAL33 cells with the HCS assay performed in Dr. Paul Johnston’s lab and these 
results are summarized in Table 7. 
 
Table 7. SAR of pSTAT3 inhibitors 
 
Compd R1 R2 cLogP pSTAT3 IC50 (μM) pSTAT1 IC50 (μM) 
3.6 3,4-Cl-Ph -C3H6- 3.41 5.50 ± 1.50 (n = 7) > 50 
3.7 4-OMe-Ph -C3H6- 2.03 4.70 ± 3.70 (n = 2) > 50 
3.8 2-Cl-Thiophen-5-yl -C3H6- 2.97 6.30 ± 1.80 (n = 2) > 50 
3.9 3-Cl-Ph -C3H6- 2.82 1.80 ± 3.60 (n = 2) > 50 
3.10 4-Cl-Ph -C3H6- 2.82 25.7 (n = 1) > 50 
3.11 4-CN-Ph -C3H6- 1.54 > 50 > 50 
3.12 Pyridine-4-yl -C3H6- 0.611 > 50 > 50 
3.13 t-Bu -C3H6- 1.91 > 50 > 50 
3.14 H -C3H6- -0.203 > 50 > 50 
N
N
N
N
NH
S
NR1
R2
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3.15 4-F-Ph -C3H6- 2.25 > 50 > 50 
3.16 Ph -C3H6- 2.11 > 30 > 50 
3.17 Indol-3-yl -C3H6- 2.10 > 50 > 50 
3.18 Me -C3H6- 0.673 > 50 > 50 
3.19 Hexanyl -C3H6- 2.61 > 50 > 50 
3.20 3,4-Cl-Ph -C4H8- 3.97 13.57 ± 3.91 (n = 4) > 50 
3.21 4-OMe-Ph -C4H8- 2.59 19.2 ± 2.10 (n = 2) > 50 
3.22 2-Cl-Thiophen-5-yl -C4H8- 3.53 33.2 ± 1.60 (n = 2) > 50 
3.23 3-Cl-Ph -C4H8- 3.38 40.5 ± 1.60 (n = 2) > 50 
3.24 4-Cl-Ph -C4H8- 3.38 13.5 ± 0.70 (n = 2) > 50 
3.25 4-F-Ph -C4H8- 2.81 > 50 > 50 
3.26 Indol-3-yl -C4H8- 2.66 27.6 ± 3.70 (n = 2) > 50 
3.27 4-CN-Ph -C4H8- 2.10 > 50 > 50 
3.28 Pyridin-4-yl -C4H8- 1.17 > 50 > 50 
3.29 t-Bu -C4H8- 2.47 > 50 > 50 
3.30 H -C4H8- 0.36 > 50 > 50 
3.31 Me -C4H8- 1.23 > 50 > 50 
3.32 Ph -C4H8- 2.67 > 50 > 50 
3.33 2-Cl-Ph -C4H8- 3.38 > 50 > 50 
3.34 3,4-Cl-Ph Ph 4.96 25.3 ± 0.01 (n = 2) > 50 
3.35 3-Cl-Ph Ph 4.37 9.80 (n = 1) > 50 
3.36 4-Cl-Ph Ph 4.37 5.60 ± 1.60 (n = 4) > 50 
3.37 4-F-Ph Ph 3.80 14.1 ± 4.20 (n = 2) > 50 
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3.38 Ph Ph 3.65 25.7 (n = 1) > 50 
3.39 Indol-3-yl Ph 3.64 4.30 ± 2.30 (n = 2) > 50 
3.40 4-CN-Ph Ph 3.09 18.3 ± 0.05 (n = 2) > 50 
3.41 2-Cl-Thiophen-5-yl Ph 4.05 > 50 > 50 
3.42 Pyridin-4-yl Ph 2.16 > 50 > 50 
3.43 H Ph 1.34 > 50 > 50 
3.44 Me Ph 2.22 > 50 > 50 
3.45 2-Cl-Ph Ph 4.37 13.9 ± 4.81 (n = 4) > 50 
3.46 t-Bu Ph 3.45 > 50 > 50 
3.47 4-OMe-Ph Ph 3.57 3.64 ± 2.13 (n = 4) > 50 
3.48 Hexanyl Ph 4.16 > 30 > 50 
3.49 3,4-Cl-Ph 4-F-Ph 5.10 14.6 ± 5.70 (n = 2) > 50 
3.50 4-Cl-Ph 4-F-Ph 4.51 16.2 ± 3.00 (n = 2) > 50 
3.51 4-F-Ph 4-F-Ph 3.94 25.6 ± 1.30 (n = 2) > 50 
3.52 4-OMe-Ph 4-F-Ph 3.72 > 50 > 50 
3.53 4-CN-Ph 4-F-Ph 3.23 > 50 > 50 
3.54 t-Bu 4-F-Ph 3.60 > 50 > 50 
3.55 Me 4-F-Ph 2.37 > 50 > 50 
3.56 Ph 4-F-Ph 3.80 > 30 > 30 
3.57 2-Cl-Thiophen-5-yl 4-F-Ph 4.20 19.2 ± 6.53 (n = 4) > 50 
3.58 3,4-Cl-Ph 4-Cl-Ph 5.68 14.5 ± 3.80 (n = 2) > 50 
3.59 4-CN-Ph 4-Cl-Ph 3.80 > 50 > 50 
3.60 Ph 4-Cl-Ph 4.37 > 50 > 50 
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3.61 2-Cl-Ph 4-Cl-Ph 5.08 25.1 ± 3.65 (n = 2) > 30 
 
As indicated in Table 7, all compounds had a pSTAT1 IC50  > 50 μM. In general, larger 
electron donating groups (EDG) such as the t-Bu group (3.13, 3.29, 3.46, 3.54) or small alkyl 
groups (3.18, 3.31, 3.44, 3.55) at the R1 position exhibited no pSTAT3 activity, and these 
analogs exhibited potential membrane-permeability issues, as most of their cLogP are less than 
2.5. In addition, the unsubstituted imines (3.14, 3.30, 3.43) were also inactive, and their cLogP 
are less than 1. Electron withdrawing groups (EWG) at the R1 position such as the pyridinyl 
(3.12, 3.28, 3.42) and cyanophenyl group (3.11, 3.27, 3.40, 3.59) showed no pSTAT3 inhibition 
and they also demonstrated lower cLogP values. Preferred electronic effects at R1 were observed 
as the unsubstituted phenyl analog had a fair potency and monosubstituted electro-donating 
groups at the meta- or para- positions were beneficial to potency. The p-Cl phenyl analogs were 
more potent than the analogous p-F compounds and the former demonstrated higher cLogP 
values (3.24 vs. 3.25, 3.36 vs. 3.37, 3.50 vs. 3.51). 
The substitution at the R2 position of the pyrazole also affected pSTAT3 potency, with 
the fused cyclopentyl-pyrazole proving to be adequate. Other replacement did not increase their 
activities, albeit their increased cLogP values. For example, replacement of the cyclopentyl-
pyrazole (3.6) with indazole (3.20), phenyl (3.34), 4-F-Phenyl (3.49) or 4-Cl-Phenyl (3.58) 
groups led to a 2- to 5-fold decrease of the inhibition of pSTAT3. Similarly, the cyclopentyl-
pyrazole (3.7) was 4-fold more active than the 4-F-phenyl-substituted pyrazole (3.52). The 2-Cl-
cyclopentyl-pyrazole analogs were also similar in terms of potency (3.8 vs. 3.22, 3.41, 3.57). 
Encouragingly, with the cyclopentapyrazole at the R2 position, compound 3.9 (3-Cl-Ph) showed 
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a 3-fold improvement in inhibitory activity of pSTAT3 over the lead compound 669, and it was 
20-fold more potent than its analog 3.23 (-C4H8-).  
The bioassay profiles for the α-methyl containing analogs are summarized in Table 8  
(3.64-3.74). Consistent with the earlier SAR results, the analogs with para-electron-donating 
groups at the R1 position maintained potencies and selectivities for pSTAT3 over pSTAT1 (3.64, 
3.71, and 3.72). In addition, the α-substitution provided increased metabolic stabilities, with 3.74 
showing a t1/2 = 26.6 min and 10.2 min in human and mouse microsomes. A 5-fold increase in 
pSTAT3 potency was also obtained for compound 3.74. Additional analogs displayed similar 
enhanced potencies and selectivities (3.52 vs. 3.71, 3.56 vs. 3.70), and they all had an increased 
cLogP values than their original analogs where the α-position of sulfur was not substituted. 
These preliminary results inspired us to further investigate this position with a larger substitution 
such as iso-propyl, benzyl, or iso-butyl groups (Table 8, 3.82-3.92). While these larger 
substituents had increased their cLogP values to around 5, the combination of the 4-OMe-Ph 
substitution at the R1 position with these substitutions maintained the pSTAT3 potencies and 
selectivities against pSTAT1 (Table 8, 3.83, 3.84, 3.86, 3.88 and 3.92). The gem-dimethyl 
substituted compounds were significantly less active (Table 9). Although the investigation of the 
non-pyrazole containing analogs are still in progress, it appears that the pyrazole is an important 
feature contributing to the activities of these inhibitors since several early MLSCN library 
compounds with phenyl- or pyridinyl- groups showed poor activity.   
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Table 8. SAR of SOM blocked pSTAT3 inhibitors of 669 analogs 
 
Compd R1 R2 R3 cLogP pSTAT3 IC50 (μM) pSTAT1 IC50 (μM) 
3.64 4-OMe-Ph -C3H6- Me 2.55 8.78 ± 0.27 (n = 2) > 50 
3.65 3,4-Cl-Ph -C3H6- Me 3.93 7.90 ± 1.27 (n = 2) > 50 
3.66 Ph -C3H6- Me 2.63 20.4 ± 4.85 (n = 3) > 50 
3.67 4-Cl-Ph -C3H6- Me 3.34 I.P. I.P. 
3.68 4-F-Ph -C3H6- Me 2.77 I.P  I.P. 
3.69 Ph -C4H8- Me 3.19 > 20 > 50 
3.70 Ph 4-F-Ph Me 4.32 3.81 ± 0.70 (n = 4) > 30 
3.71 4-OMe-Ph 4-F-Ph Me 4.24 4.16 ± 0.325 (n = 2) 31.1 ± 4.25 (n = 2) 
3.72 4-OMe-Ph 4-Cl-Ph Me 4.81 3.84 ± 0.48 (n = 2) 29.5 ± 8.40 (n = 2) 
3.73 Ph 4-Cl-Ph Me 4.89 5.69 ± 1.28 (n = 3) > 50 
3.74 Ph Ph Me 4.17 4.82 ± 0.70 (n = 2) > 50 
3.81 Ph -C3H6- Ph 3.87 I.P. I.P. 
3.82 3,4-Cl-Ph -C3H6- i-Pr 4.86 I.P. I.P. 
3.83 4-OMe-Ph -C3H6- i-Pr 3.47 2.23 (n = 1) > 50 
3.84 4-OMe-Ph Ph i-Pr 5.02 2.37 (n = 1) > 50 
3.85 3,4-Cl-Ph -C3H6- Bn 5.35 7.5 (n = 1) > 50 
3.86 4-OMe-Ph -C3H6- Bn 3.96 3.15 (n = 1) > 50 
3.87 3,4-Cl-Ph Ph Bn 6.90 22.65 (n = 1) > 50 
N
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3.88 4-OMe-Ph Ph Bn 5.51 5.78 (n = 1) > 50 
3.89 3,4-Cl-Ph Ph i-Bu 6.93 > 50 > 50 
3.90 4-OMe-Ph Ph i-Bu 5.55 13.57 (n = 1) > 50 
3.91 3,4-Cl-Ph -C3H6- i-Bu 5.39 4.14 (n =1) > 50 
3.92 4-OMe-Ph -C3H6- i-Bu 4.00 5.14 (n =1) > 50 
 
 
Table 9. SAR of geminal methyl substituted 669 analogs 
 
Compd R1 R2 cLogP pSTAT3 IC50 (μM) pSTAT1 IC50 (μM) 
3.75 Ph -C3H6- 3.15 > 50 > 50 
3.80 3,4-Cl-Ph -C3H6- 4.45 I.P. I.P. 
3.76 Ph 4-Cl-Ph 5.40 22.3 ± 11.5 (n = 2) > 50 
 
N
N
N
N
NH
S
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5.0  CONCLUSION AND PERSPECTIVES 
A first generation 669 library produced a total of 56 analogs in > 95% purity based on 
LC/MS which were submitted for inhibition of pSTAT3 and pSTAT1. The analogs with 
electron-donating para-substituents (4-OMe-Ph, 3,4-di-Cl-Ph) at the R1 position proved to be 
most potent and selective in targeting pSTAT3 over pSTAT1. Subsequent attempts to address 
metabolic liabilities led to the synthesis of another 32 compounds. The novel α-methyl-
containing compounds showed increased half-lives in both human and mouse microsomes and 
enhanced pSTAT3 inhibition. The activity and selectivity were not affected when this methyl 
group was replaced by larger iso-propyl or iso-butyl groups. However, geminal dimethyl 
substitution was not tolerated.  
Future work on this scaffold is ongoing and should consist of further SAR development 
with a focus on triazolothiadiazine modification and an emphasis on improving water solubility 
and cellular growth inhibition. 
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6.0  EXPERIMENTAL SECTION OF COMPOUND 3.6-3.104 
6.1 INDEX OF COMPOUNDS 
6-(3,4-Dichlorophenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H[1,2,4]triazolo[3,4-
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6.2 EXPERIMENTAL PROCEDURES 
General: All reactions were performed under an argon atmosphere and all glassware were dried 
in an oven at 130 °C for 2 h prior to use. EtOH was distilled over Br2/Mg turnings. Reactions 
were monitored by TLC analysis (pre-coated silica gel 60 F254 plates, 250 μm layer thickness) 
and visualization was accomplished with a 254 nm UV light and by staining with a PMA 
solution (5 g of phosphomolybdic acid in 100 mL of 95%EtOH), p-anisaldehyde solution (2.5 
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mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. H2SO4 in 100 mL of 95% EtOH), 
Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N 
H2SO4 solution) or a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a0.1% 
NaOH solution). Purifications by chromatography were performed using SiO2 (SiliaFlash ® F60, 
Silicycle) or using an ISCO-Companion flash chromatography system. Decantation was 
performed in distilled hexane. IR spectra were determined on a Smith Detection IdentifyIR FT-
IR spectrometer (ATR). 
1
H spectra were obtained at 400 MHz at 100 °C in DMSO-d6 unless 
otherwise noted. Chemical shifts were reported in parts per million with the residual solvent peak 
used as an internal standard. 
1
H NMR spectra are tabulated as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint =quintet, m = multiplet, br = 
broad), number of protons, and coupling constant(s). 
13
C NMR spectra were run at 100 MHz at 
100 °C using a proton-decoupled pulse sequence with a d1 of 3 sec, and are tabulated by 
observed peaks. Mass spectra were obtained on a Micromass Autospec double focusing 
instrument. Microwave reactions were performed using a Biotage Initiator in glass microwave 
vials (cap sealed) with continuous magnetic stirring and an external surface temperature sensor. 
LCMS analyses were completed on a Waters MicroMass ZQ with 2525 Binary Gradient Module, 
2420 ELSD, 2996 PDA using MeCN/H2O with 0.1% TFA. Melting points (uncorrected) were 
determined using a Mel-Temp instrument. 
 
 
6-(3,4-Dichlorophenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.6) 
N
N
N
N
NH
S
N
Cl
Cl
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A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0250 g, 0.112 mmol) and 2,3',4'-trichloroacetophenone (0.0251 g, 0.112 mmol) in 
EtOH (1 mL) was heated at 95 °C in a microwave for 30 min, and LC-MS analysis showed that 
the conversion was complete. The solvent was evaporated, and the resulting residue was 
dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the 
aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/ CH2Cl2) and provided 38.7 mg (88%) of 3.6 as a 
colorless powder: Mp 209 °C; IR (ATR) 3154, 2902, 1506, 1458, 818 cm
-1
; 
1
H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 8.27 (d, 1 H, J = 2.4 Hz), 7.99 (dd, J = 8.4 Hz, 2 Hz, 1 H), 7.87 (d, 1 H, J = 
8.4 Hz), 4.45 (s, 2 H), 2.73-2.68 (m, 4 H), 2.43-2.40 (m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 
100 °C) δ 153.7, 141.6, 134.0, 132.0, 131.2, 129.4, 127.6, 30.0, 24.0, 23.6, 22.9, 4 quaternary C 
were missing; HRMS (ES) m/z calcd for C16H12Cl2N6S ([M+H]
+
) 391.0299, found 391.0308. 
 
 
6-(4-Methoxyphenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.7) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 4-methoxyphenacyl chloride (0.0415 g, 0.225 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for 90 min, and LC-MS analysis showed that 
N
N
N
N
NH
S
N
O
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the conversion was complete. The solvent was evaporated, and the resulting residue was 
dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the 
aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/ CH2Cl2) and provided 62 mg (78%) of 3.7 as a colorless 
powder: Mp 251.8 °C; IR (ATR) 3415, 2941, 1605, 1517, 1450, 1277, 1178, 956 cm
-1
; 
1
H NMR 
(400 MHz, DMSO-d6, 100 °C) 7.99-7.96 (m, 2 H), 7.13-7.09 (m, 2 H), 4.34 (s, 2 H), 3.88 (s, 3 
H), 2.78-2.69 (m, 4 H), 2.47-2.42 (br m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 162.0, 
154.5, 140.8, 128.9, 125.4, 125.2, 114.1, 55.1, 29.5, 23.2, 22.7, 3 quaternary C were missing; 
HRMS (ES) m/z calcd for C17H16N6SO ([M+H]
+
) 353.1185, found 353.1176. 
 
 
6-(5-Chlorothiophen-2-yl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.8) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 2-chloro-1-(5-chlorothiophen-2-yl)ethan-1-one(0.0439 g, 
0.225 mmol) in EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, 
the reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, 
washed with H2O, and dried (Na2SO4). Decantation of the residues in dry hexane provided 44.4 
mg (54%) of 3.8 as a colorless powder: Mp 249 °C; IR (ATR) 3156, 2907, 1564, 1433, 1291, 
956 cm
-1
; 
1
H NMR (100 MHz, DMSO-d6, 100 °C) 7.80 (d, J = 4 Hz, 1 H), 7.28 (d, J = 4.4 Hz, 1 
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H), 4.38 (s, 2 H), 2.82 (br s, 2 H), δ 2.74-2.71 (m, 2 H), 2 aliphatic H overlapped with DMSO 
peak; 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 149.7, 140.8, 135.7, 134.5, 132.1, 127.8, 125.2, 
29.5, 23.7, 23.1, 22.3, 3 quaternary C were missing; HRMS (ES) m/z calcd for C14H11ClN6S2 
([M+H]
+
) 363.0253, found 363.0246. 
 
 
6-(3-Chlorophenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.9) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 2-bromo-3'-chloroacetophenone (0.0525 g, 0.225 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for 90 min, and LC-MS analysis showed that 
the conversion was complete. The solvent was evaporated, and the resulting residue was 
dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the 
aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/ CH2Cl2) and provided 31.9 mg (40%) of 3.9 as a 
colorless powder: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.65 (br s, 1 H), 8.05 (s, 1 H), 7.95 
(d, J = 8 Hz, 1 H), 7.65 (dd, J = 1.6 Hz, 6.8 Hz, 1 H), 7.59 (t, J = 7.8 Hz, 1 H), 4.40 (s, 2 H), 2.75 
(t, J = 7.2 Hz, 2 H), 2.72 (t, J = 7.2 Hz, 2 H), 2.45 (br s, 2 H); HRMS (ES) m/z calcd for 
C16H14N6SCl ([M+H]
+
) 357.0684, found 357.0675. 
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6-(4-Chlorophenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.10) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-3-
thiol (0.0500 g, 0.225 mmol) and 2,4'-dichloroacetophenone (0.0425 g, 0.225 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 34.5 mg (43%) of 3.10 as a 
colorless powder: Mp 243°C; IR (ATR) 3163, 2906, 1591, 1452, 1297, 952 cm
-1
; 
1
H NMR (400 
MHz, DMSO-d6, 100 °C) δ 12.62 (s br, 1 H), 8.02 (d, J = 8.4 Hz, 2 H), 7.62 (d, J = 8.8 Hz, 2 H), 
4.38 (s, 2 H), 2.76-2.69 (m, 4 H), 2.44 (br s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 
154.0, 140.7, 136.3, 132.1, 128.8, 128.5, 125.3, 29.5, 23.5, 23.1, 22.8, 3 quaternary C were 
missing; HRMS (ES) m/z calcd for C16H13ClN6S ([M+H]
+
) 357.0689, found 357.0688;  
 
 
4-(3-(2,4,5,6-Tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-
yl)benzonitrile (3.11) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 4-cyanophenacyl bromine (0.0504 g, 0.225 mmol) in EtOH 
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(2 mL) was heated at 95 °C in a microwave for a total of 150 min. After cooling to rt, the 
reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed 
with H2O, and dried (Na2SO4). Decantation of the residue in distilled hexane provided 43.9 mg 
(56%) of 3.11 as a colorless powder: Mp 254 °C; IR (ATR) 3167, 2912, 2226, 1452, 1294, 954, 
820 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 8.16 (d, J = 8.4 Hz, 2 H), 7.99 (d, J = 8.8 
Hz, 2 H), 4.43 (s, 2 H), 2.74 (t, J = 7.3 Hz, 2 H), 2.72 (t, J = 8.4 Hz, 2 H), 2.47-2.40 (m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 153.6, 140.7, 137.4, 132.2, 127.8, 125.4, 117.5, 
113.6, 29.5, 23.5, 23.1, 22.8, 3 quaternary C were missing; HRMS (ES) m/z calcd for C17H13N7S 
([M+H]
+
) 348.1031, found 348.1050. 
 
 
6-(Pyridin-4-yl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.12) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 4-(bromoacetyl)pyridine hydrobromide (0.0632 g, 0.225 
mmol) in EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the 
reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed 
with H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 45.8 mg (63%) 
of 3.12 as a colorless powder: Mp 273 °C; IR (ATR) 3107, 2891, 1599, 1456, 1402, 1295, 951 
cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.65 (s, NH 1 H), 8.80 (d, J = 2 Hz, 1 H), 8.79 
(d, J = 1.6 Hz, 1 H), 7.90 (d, 1 H, J = 1.6 Hz, 1 H), 7.89 (d, J = 1.6 Hz, 1 H), 4.42 (s, 2 H), 2.75 
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(t, J = 6.8 Hz, 2 H), 2.72 (t, J = 6.8 Hz, 2 H), 2.45 (br s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 
100 °C) δ 150.0, 140.7, 140.4, 120.6, 23.5, 23.1, 22.5, 1 aliphatic C and 5 quaternary C were 
missing; HRMS (ES) m/z calcd for C15H14N7S ([M+H]
+
) 324.1026, found 324.1017.  
 
 
6-(tert-Butyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.13) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 1-bromopinacolone (0.0403 g, 0.225 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for a total of 150 min. The solvent was evaporated, and the 
resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers 
were separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 41.5 mg (61%) of 
3.13 as a colorless powder: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.43 (s, NH 1 H), 3.91 (s, 
2 H), 2.75 (t, J = 6.8 Hz, 2 H), 2.70 (t, J = 7.2 Hz, 2 H), 2.46-2.43 (m, 2 H), 1.30 (s, 9 H); HRMS 
(ES) m/z calcd for C14H19N6S ([M+H]
+
) 303.1386, found 303.1380. 
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3-(2,4,5,6-Tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.14) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0700 g, 0.315 mmol) and 2-chloro-1,1-diethoxyethane (0.0872 g, 0.630 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for 150 min. The solvent was evaporated, and 
the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The 
layers were separated and the aqueous phase was re-extracted with CH2Cl2. The combined 
organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The 
resulting residue was purified by chromatography on SiO2 (10% MeOH/ CH2Cl2) and provided 
18.3 mg (23.6%) of 3.14 as a colorless powder: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.5 
(br s, 1 H), 7.86 (t, J = 4 Hz, 1 H), 3.86 (d, J = 3.86 Hz, 2 H), 2.76 (t, J = 7 Hz, 2 H), 2.70 (t, J = 
7.2 Hz, 2 H), 2.46-2.45 (m, 2 H). HRMS (ES) m/z calcd for C10H11N6S ([M+H]
+
) 247.0760, 
found 247.0752. 
 
 
6-(4-Fluorophenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.15) 
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A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 2-chloro-4'-fluoroacetophenone (0.0388 g, 0.225 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction 
mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with 
H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 38.5 mg (50%) of 
3.15 as a colorless powder: Mp 243 °C; IR (ATR) 3184, 2070, 1599, 1448, 1223, 954.3, 810.8 
cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 8.09-8.05 (m, 2 H); 7.40-7.34 (m, 2 H), 4.39 (s, 
2 H), 2.77-2.69 (m, 4 H), 2.46-2.42 (br t, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 165.2, 
162.7, 154.3, 141.0, 129.8, 129.7, 125.6, 115.7, 115.5, 30.0, 29.6, 23.6, 23.3, 23.1, 1 quaternary 
C was missing; HRMS (ES) m/z calcd for C16H13FN6S ([M+H]
+
) 341.0985, found 341.0982. 
 
 
6-Phenyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.16) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 2-chloroacetophenone (0.0348 g, 0.225 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 50.7 mg (70%) of 3.16 as a 
colorless powder: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.64 (br s, 1 H), 8.01-7.99 (m, 2 
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H); 7.63-7.54 (m, 3 H), 4.39 (s, 2 H), 2.77-2.69 (m, 4 H), 2.43 (br s, 2 H); HRMS (ES) m/z calcd 
for C16H15N6S ([M+H]
+
) 323.1073, found 323.1065. 
 
 
6-(1H-indol-3-yl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.17) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 2-chloro-1-(1H-indol-3-yl)ethan-1-one (0.0436 g, 0.225 
mmol) in EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the 
reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed 
with H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 54.1 mg (67%) 
of 3.17 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.61-12.56 (br s, NH 1 H), 11.8 (s, 
NH 1H), 8.23 (s, 1 H), 7.51 (d, J = 8.4 Hz, 1 H), 7.25 (t, J = 7.6 Hz, 1 H), 7.16 (t, J = 7.6 Hz, 1 
H), 4.33 (s, 2 H), 2.70-2.74 (br m, 4 H), 2.42 (br s, 2 H); HRMS (ES) m/z calcd for C18H15N7S 
([M+H]
+
) 362.1182, found 362.1171.     
 
 
6-Methyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.18) 
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A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and chloroacetone (0.0208 g, 0.225 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was treated 
with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 35.7 mg (61%) of 3.18 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.55 (br s, 1 H), 3.85 (s, 2 H), 2.79 (t, J = 6.8 Hz, 2 
H), 2.70 (t, J = 7.4 Hz, 2 H), 2.46-2.42 (br t, 2 H), 2.34 (s, 3 H); HRMS (ES) m/z calcd for 
C11H12N6S ([M+H]
+
) 261.0917, found 261.0909.  
 
6-Cyclohexyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.19) 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 2-bromo-1-cyclohexylethanone (0.0461 g, 0.225 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and 
the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The 
layers were separated and the aqueous phase was re-extracted with CH2Cl2. The combined 
organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The 
resulting residue was purified by chromatography on SiO2 (10% MeOH/ CH2Cl2) and provided 
61.5 mg (83%) of 3.19 as a solid: Mp 189 °C; IR (ATR) 3178, 3074, 2911, 2854, 1610, 1504 cm
-
1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 3.86 (s, 2 H), 2.76 (t, J = 8 Hz, 2 H), 2.70 (t, J = 8 
Hz, 2 H), 2.67-2.60 (m, 1 H), 2.48-2.41 (m, 2 H), 1.96-1.92 (m, 2 H), 1.84-1.79 (m, 2 H), 1.73-
1.67 (m, 1 H), 1.53-1.44 (m, 2 H), 1.42-1.31 (m, 2 H), 1.30-1.12 (m, 1 H); 
13
C NMR (100 MHz, 
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DMSO-d6, 100 °C) δ 164.1, 145.7, 141.0, 125.1, 44.8, 29.5, 28.7, 24.9, 24.7, 23.6, 23.2, 23.1, 2 
quaternary C were missing; HRMS (ES) m/z calcd for C16H21N6S ([M+H]
+
) 329.1548, found 
329.1546. 
 
 
6-(3,4-Dichlorophenyl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.20) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0250 g, 0.106 mmol) and 2,3',4'-trichloroacetophenone (0.0236 g, 0.106 mmol) in EtOH (1 
mL) was heated at 95 °C in a microwave for 30 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 39.6 mg (92%) of 3.20 as a solid: 
Mp 220 °C; IR (ATR) 3081, 2930, 2854, 1541, 1445 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 
°C) δ 8.21 (d, J = 2 Hz, 1 H), 7.95 (dd, J = 2 Hz, 8.4 Hz, 1 H), 7.79 (d, J = 8.4 Hz, 1 H), 4.38 (s, 
2 H), 2.68 (t, J = 6 Hz, 2 H), 2.66 (t, J = 6 Hz, 2 H), 1.84-1.78 (m, 2 H), 1.77-1.70 (m, 2 H); 
13
C 
NMR (100 MHz, DMSO-d6, 100 °C) δ 161.4, 152.5, 147.4, 141.0, 140.6, 133.8, 131.6, 130.6, 
128.8, 127.0, 115.4, 22.4, 22.3, 21.9, 20.7, 20.5; HRMS (ES) m/z calcd for C17H14Cl2N6S 
([M+H]
+
) 405.0456, found 405.0462. 
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6-(4-Methoxyphenyl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.21) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 4-methoxyphenacyl chloride (0.0391 g, 0.212 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the 
resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers 
were separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 75.1 mg (97%) of 
3.21 as a solid: Mp 148 °C; IR (ATR) 3067, 2999, 2843, 1603, 1448, 1255, 1176 cm
-1
; 
1
H NMR 
(400 MHz, DMSO-d6, 100 °C) δ 7.98-7.94 (m, 2 H), 7.10-7.07 (m, 2 H), 4.32 (s, 2 H), 3.87 (s, 3 
H), 2.68 (t, J = 6 Hz, 2 H), 2.65 (t, J = 6 Hz, 2 H), 1.84-1.75 (m, 4 H); 
13
C NMR (100 MHz, 
DMSO-d6, 100 °C) δ 161.9, 154.0, 147.2, 140.7, 128.8, 125.5, 115.3, 114.0, 55.1, 22.5, 22.4, 
21.9, 20.8, 20.5, 2 quaternary C were missing; HRMS (ES) m/z calcd for C18H18N6SO ([M+H]
+
) 
367.1341, found 367.1332. 
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6-(5-Chlorothiophen-2-yl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.22) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2-chloro-1-(5-chlorothiophen-2-yl)ethan-1-one (0.0413 g, 0.212 
mmol) in EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 63.8 mg (80%) of 3.22 as a solid: Mp 265.3 °C; 
1
H NMR (400 MHz, DMSO-d6, 100 
°C) δ 7.77 (d, J = 4 Hz, 1 H), 7.25 (d, J = 4.4 Hz, 1 H), 4.37 (s, 2 H), 2.69-2.63 (m, 4 H), 1.84-
1.80 (m, 2 H), 1.79-1.74 (m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 149.1, 140.4, 
136.0, 134.3, 131.6, 127.6, 115.2, 22.3, 22.1, 21.9, 20.4, 1 aliphatic C and 2 quaternary C were 
missing; HRMS (ES) m/z calcd for C15H13N6S2Cl ([M+H]
+
) 377.0410, found 377.0407. 
 
 
6-(3-Chlorophenyl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.23) 
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A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2-bromo-3'-chloroacetophenone (0.0494 g, 0.212 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 38.2 mg (49%) of 3.23 as a solid: 
Mp 160 °C; IR (ATR) 3144, 2932, 1560, 1445, 781 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 
°C) δ 8.03 (s, 1 H), 7.94 (d, J = 8 Hz, 1 H), 7.65-7.62 (m, 1 H), 7.57 (t, J = 7.8 Hz, 1 H), 4.32 (s, 
2 H), 2.68 (t, J = 5.6 Hz, 2 H), 2.66 (t, J = 5.6 Hz, 2 H), 1.84-1.78 (m, 1 H), 1.77-1.71 (m, 1 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 153.2, 140.7, 135.4, 133.4, 130.8, 126.6, 125.7, 22.6, 
22.4, 21.9, 20.5, 1 aliphatic and 4 quaternary carbon were missing; HRMS (ES) m/z calcd for 
C17H16N6SCl ([M+H]
+
) 371.0846, found 371.0854. 
 
 
6-(4-Chlorophenyl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.24) 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2,4'-dichloroacetophenone (0.0400 g, 0.212 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for a total of 120 min. After cooling to rt, the reaction 
mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with 
H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 54.6 mg (70%) of 
3.24 as a solid: Mp 255 °C; IR (ATR) 3197, 2928, 1558, 1441, 850 cm
-1
; 
1
H NMR (400 MHz, 
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DMSO-d6, 100 °C) δ 8.02-7.99 (m, 2 H), 7.61-7.58 (m, 2 H), 4.37 (s, 2 H), 2.69-2.63 (m, 4 H), 
1.84-1.75 (m, 4H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 153.5, 147.4, 141.0, 140.7, 136.2, 
132.2, 132.1, 128.7, 128.4, 115.4, 22.5, 22.3, 21.9, 20.7, 20.5; HRMS (ES) m/z calcd for 
C17H16ClN6S ([M+H]
+
) 371.0846, found 371.0854. 
 
 
6-(4-Fluorophenyl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.25) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2-chloro-4'-fluoroacetophenone (0.0370 g, 0.212 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 50.1 mg (72%) of 3.25 as a solid: 
Mp 253 °C; IR (ATR) 3161, 2932, 1597, 1450, 1225, 848 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100°C) δ 8.08-8.04 (m, 2 H), 7.38-7.34 (m, 2 H), 4.37 (s, 2 H), 2.67 (t, J = 6.4 Hz, 2 H), 2.65 (t, 
J = 6.4 Hz, 2 H), 1.84-1.74 (m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 165.0, 162.5, 
153.6, 147.4, 141.1, 140.7, 132.3, 129.8, 129.8, 129.6, 129.5, 22.6, 22.3, 21.9, 20.7, 20.5; HRMS 
(ES) m/z calcd for C17H16FN6S ([M+H]
+
) 355.1141, found 355.1146. 
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6-(1H-indol-3-yl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.26) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2-chloro-1-(1H-indol-3-yl)ethan-1-one (0.0410 g, 0.212 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for a total of 120 min. After cooling to rt, the 
reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed 
with H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 47.8 mg (60%) 
of 3.26 as a solid: Mp 307 °C; IR (ATR) 2917, 1556, 1445, 1240, 744 cm
-1
; 
1
H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 8.38 (d, J = 8 Hz, 1 H), 8.19 (s, 1 H), 7.47 (d, J = 8 Hz, 1 H), 7.20 (t, J = 
7.2 Hz, 1 H), 7.11 (t, J = 7.6 Hz, 1 H), 4.30 (s, 2 H), 2.72 (t, J = 6.4 Hz, 2 H), 2.67 (t, J = 6 Hz, 2 
H), 1.85-1.79 (m, 2 H), 1.79-1.71 (m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 151.7, 
140.4, 137.0, 131.2, 124.0, 122.5, 120.7, 115.1, 111.4, 110.3, 22.9, 22.3, 21.9, 20.4, 1 aliphatic C 
and 4 quaternary C were missing; HRMS (ES) m/z calcd for C19H17N7S ([M+H]
+
) 376.1344, 
found 376.1337. 
 
 
4-(3-(4,5,6,7-Tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)benzonitrile 
(3.27) 
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A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 4-cyanophenacyl bromine (0.0474 g, 0.212 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting 
residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were 
separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic phases 
were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was 
purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 56.1 mg (73%) of 3.27 
as a solid: Mp 250 °C; IR (ATR) 2927, 2228, 1450, 1286, 818 cm
-1
; 
1
H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 8.15 (d, J = 8.4 Hz, 2 H), 7.97 (d, J = 8.4 Hz, 2 H), 4.41 (s, 2 H), 2.67 (t, J 
= 6.4 Hz, 2 H), 2.66 (t, J = 6 Hz, 2 H), 1.84-1.74 (m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 
°C) δ 153.1, 147.6, 140.6, 137.5, 132.2, 127.7, 117.5, 115.4, 113.5, 22.5, 22.3, 21.9, 20.7, 20.5, 2 
quaternary C were missing; HRMS (ES) m/z calcd for C18H15N7S ([M+H]
+
) 362.1188, found 
362.1227. 
 
 
6-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.28) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 4-(bromoacetyl)pyridine hydrobromide (0.069 g, 0.212 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and 
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the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The 
layers were separated and the aqueous phase was re-extracted with CH2Cl2. The combined 
organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The 
resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 
36 mg (50%) of 3.28 as a solid: Mp 232 °C; IR (ATR) 3145, 2925, 1592, 1452, 1288, 807 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.64 (br s, NH 1 H), 8.78-8.77 (m. 2 H), 7.88 (d, J = 
6 Hz, 2 H), 4.40 (s, 2 H), 2.68 (t, J = 6.4 Hz, 2 H), 2.66 (t, J = 6 Hz, 2 H), 1.84-1.80 (m, 2 H), 
1.79-1.75 (m, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 152.8, 150.0, 140.7, 140.5, 120.6, 
115.4, 22.3, 21.9, 20.5, 1 aliphatic C and 2 quaternary C were missing; HRMS (ES) m/z calcd for 
C16H15N7S ([M+H]
+
) 338.1188, found 338.1185. 
 
 
6-(tert-Butyl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.29) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 1-bromopinacolone (0.0379 g, 0.212 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for a total of 150 min. The solvent was evaporated, and the 
resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers 
were separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 34.9 mg (52%) of 
3.29 as a solid: Mp 209 °C; IR (ATR) 3411, 2930, 1452, 960, 818 cm
-1
; 
1
H NMR (100 MHz, 
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DMSO-d6, 100 °C) δ 12.54 (br s, 1 H), 3.90 (s, 2H), 2.67-2.61 (m, 4 H), 1.83-1.69 (m, 4 H), 1.28 
(s, 9 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 166.1, 141.2, 115.2, 38.4, 26.3, 22.4, 22.0, 
21.4, 20.4, 3 quaternary C were missing; HRMS (ES) m/z calcd for C15H20N6S ([M+H]
+
) 
317.1548, found 317.1550. 
 
 
3-(4,5,6,7-Tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.30) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.100 g, 0.423 mmol) and 2-chloro-1,1-diethoxyethane (127 uL, 0.846 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting 
residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were 
separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic phases 
were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was 
purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 47.1 mg (43%) of 3.30 
as a solid: Mp 264 °C; IR (ATR) 3184, 2934, 1558, 1456, 954 cm
-1
; 
1
H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 12.5 (s, NH 1 H), 7.83 (t, J = 4 Hz, 1 H), 3.83 (d, J = 4 Hz, 2 H), 2.67-2.60 
(m, 4 H), 1.83-1.75 (m, 4 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 148.1, 140.4, 115.3, 
22.3, 21.9, 21.6, 20.4, 1 aliphatic C and 3 quaternary C were missing; HRMS (ES) m/z calcd for 
C11H12N6S ([M+H]
+
) 261.0917, found 261.0910. 
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6-Methyl-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.31) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and chloroacetone (16.8 uL, 0.212 mmol) in EtOH (2 mL) was heated at 
95 °C in microwave for 90 min. The solvent was evaporated, and the resulting residue was 
dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the 
aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 51.9 mg (89%) of 3.31 as a solid: 
Mp 246 °C; IR (ATR) 3081, 2930, 1556, 1454, 1284, 954 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 3.80 (s, 2 H), 2.66-2.59 (m, 4 H), 2.31 (s, 3 H), 1.82-1.74 (m, 4 H); 13C NMR (100 
MHz, DMSO-d6, 100 °C) δ 157.8, 140.2, 115.5, 25.0, 22.5, 22.5, 22.0, 20.6, 1 aliphatic C and 3 
quaternary C were missing; HRMS (ES) m/z calcd for C12H14N6S ([M+H]
+
) 275.1079, found 
275.1082. 
 
 
6-Phenyl-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.32) 
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A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2-chloroacetophenone (24.7 uL, 0.212 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting residue 
was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and 
the aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed 
with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 64 mg (90%) of 3.32 as a solid: Mp 
190 °C; IR (ATR) 3139, 2923, 1452, 1290, 950.6 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) 
δ 12.61 (s, NH 1H), 7.99 (d, J = 7.2 Hz, 2 H), 7.61-7.53 (m, 3 H), 4.37 (s, 2 H), 2.69-2.66 (m, 4 
H), 1.84-1.74 (m, 4 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 154.5, 140.8, 133.3, 131.0, 
128.3, 127.0, 115.3, 22.7, 22.4, 21.9, 20.5, 1 aliphatic C and 3 quaternary C were missing; 
HRMS (ES) m/z calcd for C17H16N6S ([M+H]
+
) 337.1235, found 337.1194. 
 
 
6-(2-Chlorophenyl)-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.33) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2-bromo-2'-chloroacetophenone (0.0494 g, 0.212 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the 
resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers 
were separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic 
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phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 69.9 mg (89%) of 
3.33 as a solid: Mp 268 °C; IR (ATR) 3413, 2930, 1446, 1128, 761 cm
-1
; 
1
H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 12.54 (br s, 1 H), 7.63-7.47 (m, 4 H), 4.25 (s, 2 H), 2.64 (t, J = 6.3 Hz, 2 
H), 2.64 (t, J = 6.2 Hz, 2 H), 1.81-1.71 (m, 4 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 
155.2, 147.8, 140.9, 134.3, 131.5, 130.9, 130.4, 129.5, 127.0, 115.4, 25.7, 22.3, 21.8, 20.6, 20.4, 
2 quaternary C were missing; HRMS (ES) m/z calcd for C17H16N6SCl ([M+H]
+
) 371.0846, found 
371.0840. 
 
6-(3,4-Dichlorophenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.34) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2,3',4'-trichloroacetophenone (0.0433 g, 0.194 mmol)  in EtOH (2 mL) was 
heated at 95 °C in a microwave for a total of 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 54 mg (65%) of 3.34 as a solid: Mp 
270 °C;IR (ATR) 3145, 3065, 1450, 1299, 807.2 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 
13.63 (br s, NH 1 H), 8.28 (d, J = 2 Hz, 1 H), 8.03 (dd, J = 8.4 Hz, 2 Hz, 1 H), 7.84 (d, J = 7.2 
Hz, 2 H), 7.83 (d, J = 8.4 Hz, 1 H), 7.48 (t, J = 7.6 Hz, 2 H), 7.38 (t, J = 7.4 Hz, 1 H), 7.23 (s, 1 
H), 4.44 (s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 141.0, 134.2, 133.8, 131.7, 130.7, 
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129.0, 128.3, 127.6, 127.1, 124.9, 102.7, 22.6, 5 quaternary C were missing; HRMS (ES) m/z 
calcd for C19H13N6SCl2 ([M+H]
+
) 427.0299, found 427.0305. 
 
 
6-(3-Chlorophenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.35) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-bromo-3'-chloroacetophenone (0.0452 g, 0.194 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 120 min. After cooling to rt, the reaction mixture was treated 
with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 55.9 mg (73.5%) of 3.35 as a solid: 
Mp 237 °C; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.6 (s, 1 H), 8.10 (s, 1 H), 8.01 (d, 1 H, J 
= 7.6 Hz), 7.84 (d, J = 7.6 Hz, 2 H), 7.68-7.60 (m, 2 H), 7.48 (t, J = 7.6 Hz, 2 H), 7.38 (t, J = 7.2 
Hz, 1 H), 7.23 (s, 1 H), 4.44 (s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 141.1, 135.3, 
133.5, 130.9, 130.3, 128.3, 127.6, 126.8, 125.7, 124.9, 102.7, 22.7, 5 quaternary C were missing; 
HRMS (ES) m/z calcd for C19H14N6SCl ([M+H]
+
) 393.0689, found 393.0673. 
 
 
6-(4-Chlorophenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.36) 
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A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2,4'-dichloroacetophenone (0.0366 g, 0.194 mmol) in EtOH (2 mL) was heated 
at 95 °C in a microwave for 90 minutes. After cooling to rt, the reaction mixture was treated with 
sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried (Na2SO4). 
Decantation of the residue in dry hexane provided 62.6 mg (82%) of 3.36 as a solid: Mp 259 °C; 
IR (ATR) 3133, 2913, 1588, 1450, 1092, 960 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 
13.58 (s, NH 1 H), 8.07 (d, J = 8.4 Hz, 2 H), 7.84 (d, J = 6.8, 2 H), 7.65 (d, J = 8.8 Hz, 2 H), 7.48 
(t, J = 7.2 Hz, 2 H), 7.38 (t, J = 7.2 Hz, 1 H), 7.21 (s, 1 H), 4.42 (s, 2 H); 
13
C NMR (100 MHz, 
DMSO-d6, 100 °C) δ 141.0, 136.4, 132.0, 128.8, 128.3, 127.6, 125.0, 102.6, 22.6, 5 quaternary C 
were missing; HRMS (ES) m/z calcd for C19H13N6SCl ([M+H]
+
) 393.0684, found 393.0675. 
 
 
6-(4-Fluorophenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.37) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-chloro-4'-fluoroacetophenone (0.0334 g, 0.194 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was treated 
with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 33.7 mg (46%) of 3.37 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.58 (br s, 1 H), 8.14 (d, J = 5.6 Hz, 1 H), 8.12 (d, J 
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= 5.6 Hz, 1 H), 7.84 (d, J = 7.2 Hz, 2 H), 7.48 (t, J = 7.6 Hz, 2 H), 7.42-7.36 (m, 3 H), 7.22 (s, 1 
H), 4.42 (s, 2 H); HRMS (ES) m/z calcd for C19H13N6SF ([M+H]
+
) 377.0979, found 377. 0971.  
 
 
6-Phenyl-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.38) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-chloroacetophenone (0.0299 g, 0.194 mmol) in EtOH (2 mL) was heated at 
95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was treated with sat. 
Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried (Na2SO4). 
Decantation of the residue in dry hexane provided 51.1 mg (73.7%) of 3.38 as a solid: Mp 237 
°C; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.59 (s, 1 H), 8.06 (d, J = 6.4 Hz, 2 H), 7.84 (d, J 
= 7.6 Hz, 2 H), 7.64-7.57 (m, 3 H), 7.47 (t, J = 7.6 H, 2 H), 7.37 (t, J = 7.0 Hz, 1 H), 7.23 (s, 1 
H), 4.43 (s, 2 H); HRMS (ES) m/z calcd for C19H15N6S ([M+H]
+
) 359.1073, found 359.1057.  
 
 
6-(1H-indol-3-yl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.39) 
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A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-chloro-1-(1H-indol-3-yl)ethan-1-one (0.0375 g, 0.194 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 52.9 mg (69%) of 3.39 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 11.81 (br s, 1 H), 8.52 (d, J = 8 Hz, 1 H), 8.28 (d, J = 
3.2 Hz, 1 H), 7.86 (d, J = 7.2 Hz, 2 H), 7.54 (d, J = 8 Hz, 1 H), 7.48 (t, J = 7.6 Hz, 2 H), 7.40 (s, 
1 H), 7.38 (t, J = 7.2 Hz, 1 H), 7.28 (t, J = 7.6 Hz, 1 H), 7.16 (t, J = 7.6 Hz, 1 H), 4.37 (s, 2 H); 
HRMS (ES) m/z calcd for C21H15N7S ([M+H]
+
) 398.1182, found 398.1171.  
 
4-(3-(3-Phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)benzonitrile (3.40) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 4-cyanophenacyl bromine (0.0434 g, 0.194 mmol) in EtOH (2 mL) was heated 
at 95 °C in a microwave for a total of 90 minutes. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 49.8 mg (67%) of 3.40 as a solid: 
Mp 274 °C; IR (ATR) 3145, 2964, 2230, 1450, 962, 818 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 8.21 (d, J = 8.8 Hz, 2 H), 8.01 (d, J = 8.4 Hz, 2 H), 7.83 (d, J = 7.2 Hz, 2 H), 7.47 (t, J 
= 7.6 Hz, 2 H), 7.37 (t, J = 7.4 Hz, 1 H), 7.21 (s, 1 H), 4.46 (s, 2 H); 
13
C NMR (100 MHz, 
DMSO-d6, 100 °C) δ 153.7, 141.0, 137.4, 132.2, 128.3, 127.8, 127.6, 125.0, 117.4, 113.6, 102.7, 
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22.6, 4 quaternary C were missing; HRMS (ES) m/z calcd for C20H13N7S ([M+H]
+
) 384.1031, 
found 384.1025. 
 
 
6-(5-Chlorothiophen-2-yl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.41) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-chloro-1-(5-chlorothiophen-2-yl)ethan-1-one(0.0378 g, 0.194 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for a total of 90 minutes. After cooling to rt, 
the reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, 
washed with H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 59.4 
mg (77%) of 3.41 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.64 (br s, 1 H), 7.83 
(m, 3 H), 7.49-7.42 (m, 2 H), 7.38 (s, 1 H), 7.29-7.28 (m, 1 H), 7.19 (s, 1 H), 4.42 (s, 2 H); 
HRMS (ES) m/z calcd for C17H11N6S2Cl ([M+H]
+
) 399.0248, found 399.0241. 
 
 
3-(3-Phenyl-1H-pyrazol-5-yl)-6-(pyridin-4-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.42) 
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A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 4-(bromoacetyl)pyridine hydrobromide (0.0544 g, 0.194 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for a total of 90 minutes. After cooling to rt, the 
reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed 
with H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 50.1 mg (72%) 
of 3.42 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.6 (br s, 1 H), 8.82 (d, J = 5.6 Hz, 
2 H), 7.95 (d, J = 4.8 Hz, 2 H), 7.85 (d, J = 7.2 Hz, 2 H), 7.48 (t, J = 7.2 Hz, 2 H), 7.38 (t, J = 6.8 
Hz, 1 H), 7.23 (s, 1 H), 4.45 (s, 2 H); HRMS (ES) m/z calcd for C18H13N7S ([M+H]
+
) 360.1026, 
found 360.1015.   
 
 
3-(3-Phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.43) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0700 g, 
0.271 mmol) and 2-chloro-1,1-diethoxyethane (0.0751 g, 0.542 mmol) in EtOH (3 mL) was 
heated at 95 °C in a microwave for 150 min. The solvent was evaporated, and the resulting 
residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were 
separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic phases 
were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was 
purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 51.9 mg (67.8%) of 
3.43 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.5 (br s, 1 H), 7.93 (br s, 1 H), 7.82 
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(d, J = 7.2 Hz, 2 H), 7.46 (t, J = 7.6 Hz, 2 H), 7.37 (t, J = 7.0 Hz, 1 H), 7.16 (s, 1 H), 3.90 (d, J = 
4 Hz, 2 H); HRMS (ES) m/z calcd for C13H11N6S ([M+H]
+
) 283.0760, found 283.0750.  
 
 
6-Methyl-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.44) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and chloroacetone (0.0179 g, 0.194 mmol) in EtOH (2 mL) was heated at 95 °C in 
a microwave for 90 min. The solvent was evaporated, and the resulting residue was dissolved in 
CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the aqueous 
phase was re-extracted with CH2Cl2. The combined organic phases were washed with brine, 
dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 51.4 mg (90%) of 3.44 as a solid: 
1
H NMR (100 MHz, DMSO-d6, 100 °C) δ 13.48 (s, NH 1 H), 7.84 (d, J = 7.2 Hz, 2 H), 7.46 (t, J 
= 7.4 Hz, 2 H), 7.37 (t, J = 7.2 Hz, 1 H), 7.19 (s, 1 H), 3.88 (s, 2 H), 2.39 (s, 3 H); HRMS (ES) 
m/z calcd for C14H12N6S ([M+H]
+
) 297.0917, found 297.0909. 
 
 
6-(2-Chlorophenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.45) 
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A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-bromo-2'-chloroacetophenone (0.0452 g, 0.194 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 120 min. After cooling to rt, the reaction mixture was treated 
with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 56.6 mg (74.4%) of 3.45 as a solid: 
Mp 223 °C; IR (ATR) 3059, 1454, 1303, 1199, 755 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 
°C) δ 7.78 (d, J = 7.6 Hz, 2 H), 7.73 (d, J = 7.6 Hz, 1 H), 7.65 (d, J = 7.6 Hz, 1 H), 7.60 (t, J = 
7.6 Hz, 1 H), 7.53 (t, J = 7.6 Hz, 1 H), 7.45 (t, J = 7.2 Hz, 2 H), 7.35 (t, J = 7.2 Hz, 1 H), 7.16 (s, 
1 H), 4.30 (s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 155.8, 141.2, 134.1, 131.6, 130.9, 
130.5, 129.7, 128.3, 127.5, 124.9, 102.6, 25.7, 4 quaternary C were missing; HRMS (ES) m/z 
calcd for C19H14N6SCl ([M+H]
+
) 393.0689, found 393.0707. 
 
 
6-(Tert-butyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.46) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 1-bromopinacolone (0.0375 g, 0.194 mmol)  in EtOH (2 mL) was heated at 95 
°C in a microwave for 90 min. The solvent was evaporated, and the resulting residue was 
dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the 
aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed with 
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brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 59.1 mg (90%) of 3.46 as a solid: 
1
H NMR (100 MHz, DMSO-d6, 100 °C) δ 13.56 (br s, NH 1 H), 7.80 (d, J = 7.6 Hz, 2 H), 7.47 
(t, J = 7.4 Hz, 2 H), 7.36 (t, J = 7.2 Hz, 1 H), 7.20 (s, 1 H), 3.97 (s, 3 H), 1.35 (s, 9 H); HRMS 
(ES) m/z calcd for C17H18N6S ([M+H]
+
) 339.1386, found 339.1377.  
 
 
6-(4-Methoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.47) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 4-methoxyphenacyl chloride (0.0357 g, 0.194 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for a total of 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 50 mg (67%) of 3.47 as a solid: Mp 
258 °C; IR (ATR) 3061, 2911, 1605, 1450, 1256, 960 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 
°C) δ 8.04 (d, J = 9.2 Hz, 2 H), 7.84 (d, J = 7.2 Hz, 2 H), 7.47 (t, J = 7.2 Hz, 2 H), 7.37 (t, J = 7.4 
Hz, 1 H), 7.21 (s, 2 H), 7.13 (d, J = 9.2 Hz, 2 H), 4.38 (s, 2 H), 3.89 (s, 3 H); 
13
C NMR (100 
MHz, DMSO-d6, 100 °C) δ 162.0, 154.7, 141.1, 128.9, 128.3, 127.5, 125.4, 124.9, 114.2, 102.5, 
55.1, 22.6, 4 quaternary C were missing; HRMS (ES) m/z calcd for C20H16N6SO ([M+H]
+
) 
389.1179, found 389.1169. 
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6-Cyclohexyl-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.48) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-bromo-1-cyclohexylethanone (0.0397 g, 0.194 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting residue 
was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and 
the aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed 
with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 55.9 mg (79.2%) of 3.48 as a solid 
powder: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 7.81 (d, J = 7.2 Hz, 2 H), 7.47 (t, J = 7.2 Hz, 
2 H), 7.18 (s, 1 H), 3.37 (t, J = 7.2 Hz, 1 H), 3.90 (s, 2 H), 2.71-2.65 (m, 1 H), 2.04-2.00 (m, 2 
H), 1.84 (m, 2 H), 1.73-1.68 (m, 2 H), 1.59-1.50 (m, 2 H), 1.46-1.28 (m, 3 H); HRMS (ES) m/z 
calcd for C19H21N6S ([M+H]
+
) 365.1543, found 365.1529. 
 
 
6-(3,4-Dichlorophenyl)-3-(3-(4-fluorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.49) 
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A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0250 g, 0.0905 mmol) and 2,3',4'-trichloroacetophenone (0.0202 g, 0.0905 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for a total of 60 min. After cooling to rt, the reaction 
mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with 
H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 50.1 mg (72%) of 
3.49 as a solid: Mp 261 °C; IR (ATR) 3353, 2913, 1607, 1443, 1226, 840.6 cm
-1
; 
1
H NMR (100 
MHz, DMSO-d6, 100 °C) δ 13.62 (s, NH 1H), 8.27 (d, J = 2 Hz, 1 H), 8.03 (dd, J = 8.4 Hz, 2 Hz, 
1 H), 7.88 (td, J = 5.2 Hz, 2 Hz, 3.6 Hz, 2 H), 7.83 (d, J = 8.8 Hz, 1 H), 7.27 (t, J = 9 Hz, 2 H), 
7.21 (s, 1 H), 4.44 (s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 162.9, 160.4, 153.2, 
141.0, 134.2, 133.7, 131.7, 130.7, 129.0, 127.1, 127.0, 115.3, 115.1, 102.7, 22.6, 2 quaternary C 
were missing; HRMS (ES) m/z calcd for C19H11N6SCl2F ([M+H]
+
) 445.0205, found 445.0214. 
 
6-(4-Chlorophenyl)-3-(3-(4-fluorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.50) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 2,4'-dichloroacetophenone (0.0342 g, 0.181 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 41.1 mg (55.3%) of 3.50 as a solid: 
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1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.6 (br s, 1 H), 8.08 (d, J = 8.4 Hz, 2 H), 7.89 (dd, J 
= 5.6 Hz, 8.4 Hz, 2 H), 7.64 (d, J = 8.8 Hz, 2 H), 7.28 (d, J = 8.8 Hz, 1 H), 7.26 (d, J = 8.4 Hz, 1 
H), 7.20 (s, 1 H), 4.24 (s, 2 H). HRMS (ES) m/z calcd for C19H13N6SClF ([M+H]
+
) 411.0589, 
found 411.0573. 
 
 
6-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.51) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 2-chloro-4'-fluoroacetophenone (0.0312 g, 0.181 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 40.3 mg (56.5%) of 3.51 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.61 (br s, 1 H), 8.14 (d, J = 7.2 Hz, 1 H), 8.12 (d, J 
= 5.6 Hz, 1 H), 7.89 (d, J = 7.6 Hz, 1 H), 7.87 (d, J = 5.2 Hz, 1 H), 7.41 (d, J = 8.8 Hz, 1 H), 7.39 
(d, J = 8.4 Hz, 1 H), 7.29 (d, J = 8.4 Hz, 1 H), 7.26 (d, J = 8.4 Hz, 1 H), 7.20 (s, 1 H), 4.24 (s, 2 
H); HRMS (ES) m/z calcd for C19H13N6SF2 ([M+H]
+
) 395.0885, found 395.0872.  
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3-(3-(4-Fluorophenyl)-1H-pyrazol-5-yl)-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.52) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 4-methoxyphenacyl chloride (0.0334 g, 0.181 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 44.2 mg (60.1%) of 3.52 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.59 (br s, 1 H), 8.04 (d, J = 8.4 Hz, 2 H), 7.88 (t, J = 
4 Hz, 2 H), 7.27 (t, J = 8 Hz, 2 H), 7.21 (br s, 1 H), 7.13 (d, J = 8.8 Hz, 2 H), 4.38 (s, 2 H), 3.89 
(s, 3 H). HRMS (ES) m/z calcd for C20H16N6SOF ([M+H]
+
) 407.1085, found 407.1067. 
 
 
4-(3-(3-(4-Fluorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)benzonitrile 
(3.53) 
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A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 4-cyanophenacyl bromine (0.0405 g, 0.181 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for a total of 90 min. After cooling to rt, the reaction mixture 
was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and 
dried (Na2SO4). Decantation of the residue in dry hexane provided 28.2 mg (39%) of 3.53 as a 
solid: Mp 279 °C; IR (ATR) 3141, 2914, 2230, 1458, 815 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 13.65 (s, NH 1H), 8.22 (d, J = 8 Hz, 2 H), 8.02 (d, J = 8.4 Hz, 2 H), 7.88 (br t, 2 H), 
7.27 (br t, 2 H), 7.21 (s, 1 H), 4.47 (s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 132.3, 
127.9, 127.1, 117.5, 115.2, 115.1, 113.7, 102.7, 22.7, 5 quaternary C were missing; HRMS (ES) 
m/z calcd for C20H12N7SF ([M+H]
+
) 402.0937, found 402.0992. 
 
 
6-(Tert-butyl)-3-(3-(4-fluorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.54) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 1-bromopinacolone (0.0324 g, 0.181 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting residue 
was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and 
the aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed 
with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
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chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 53.2 mg (82.5%) of 3.54 as a solid: 
Mp 264 °C; IR (ATR) 3152, 2919, 1609, 1441, 1212, 835 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 13.57 (s, 1 H), 7.85 (d, J = 5.6 Hz, 1 H), 7.83 (d, J = 5.6 Hz, 1 H), 7.28 (d, J = 8.4 Hz, 
1 H), 7.26 (d, J = 8.8 Hz, 1 H), 7.17 (s, 1 H), 3.97 (s, 2 H), 1.35 (s, 9 H); 
13
C NMR (100 MHz, 
DMSO-d6, 100 °C) δ 162.8, 160.4, 126.9, 115.3, 115.1, 102.4, 38.7, 26.3, 21.5, 5 quaternary C 
were missing; HRMS (ES) m/z calcd for C17H18N6SF ([M+H]
+
) 357.1298, found 357.1315. 
 
 
3-(3-(4-Fluorophenyl)-1H-pyrazol-5-yl)-6-methyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.55) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and chloroacetone (0.0167 g, 0.181 mmol) in EtOH (2 mL) was heated 
at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting residue was 
dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the 
aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 18.3 mg (32.2%) of 3.55 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 7.89 (d, J = 5.2 Hz, 1 H), 7.87 (d, J = 5.6 Hz, 1 H), 
7.27 (d, J = 8.8 Hz, 1 H), 7.25 (d, J = 8.8 Hz, 1 H), 7.18 (s, 1 H), 3.88 (s, 2 H), 2.39 (s, 3 H); 
HRMS (ES) m/z calcd for C14H12N6SF ([M+H]
+
) 315.0823, found 315.0816.  
 
N
N
S
N
N
N
NH
F
  80 
 
3-(3-(4-Fluorophenyl)-1H-pyrazol-5-yl)-6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.56) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 2-chloroacetophenone (0.0280 g, 0.181 mmol) in EtOH (2 mL) was 
heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was treated 
with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 46.9 mg (68.9%) of 3.56 as a solid: 
Mp 260 °C; IR (ATR) 3144, 2913, 1605, 1443, 1215, 962 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 8.06 (d, J = 6.8 Hz, 2 H), 7.88 (t, J = 6 Hz, 2 H), 7.57-7.63 (m, 3 H), 7.28 (d, J = 8.4 
Hz, 1 H), 7.26 (d, J = 8 Hz, 1 H), 7.21 (s, 1 H), 4.43 (s, 2 H); 
13
C NMR (100 MHz, DMSO-d6, 
100 °C) δ 162.8, 160.4, 133.2, 131.2, 128.5, 127.1, 127.0, 115.3, 115.1, 102.6, 22.8, 4 quaternary 
C were missing; HRMS (ES) m/z calcd for C19H14N6SF ([M+H]
+
) 377.0985, found 393.0967. 
 
 
6-(5-Chlorothiophen-2-yl)-3-(3-(4-fluorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.57) 
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A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 2-chloro-1-(5-chlorothiophen-2-yl)ethan-1-one (0.0353 g, 0.181 
mmol) in EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. After cooling to rt, the 
reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was filtered, washed 
with H2O, and dried (Na2SO4). Decantation of the residue in dry hexane provided 44.5 mg 
(59.0%) of 3.57 as a solid: Mp 280 °C; IR (ATR) 3070, 2857, 1607, 1428, 1219, 961.8 cm
-1
; 
1
H 
NMR (400 MHz, DMSO-d6, 100 °C) δ 13.63 (br s, 1 H), 7.89 (d, J = 5.6 Hz, 1 H), 7.87 (d, J = 
5.6 Hz, 1 H), 7.82 (d, J = 3.6 Hz, 1 H), 7.31-7.27 (m, 3 H), 7.17 (s, 1 H), 4.42 (s, 2 H); 
13
C NMR 
(100 MHz, DMSO-d6, 100 °C) δ 162.9, 160.4, 149.8, 135.9, 134.8, 127.9, 126.9, 115.3, 102.4, 
22.2 cm
-1
, 5 quaternary C were missing; HRMS (ES) m/z calcd for C17H11N6S2FCl ([M+H]
+
) 
417.0159, found 417.0155. 
 
 
3-(3-(4-Chlorophenyl)-1H-pyrazol-5-yl)-6-(3,4-dichlorophenyl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.58) 
 
A solution of 4-amino-5-(5-(4-chloro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-
thiol (0.0250 g, 0.0854 mmol) and 2,3',4'-trichloroacetophenone (0.0191 g, 0.0854 mmol) in 
EtOH (1 mL) was heated at 95 °C in a microwave for 30 min. The solvent was evaporated, and 
the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The 
layers were separated and the aqueous phase was re-extracted with CH2Cl2. The combined 
N
N
S
N
N
N
NH
Cl
Cl
Cl
  82 
organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The 
resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 
27.3 mg (69%) of 3.58 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 80 °C) δ 13.83 (s, NH 1 H), 
8.29 (br d, 1 H), 8.05 (br s, 1 H), 7.87 (br s, 3 H), 7.40 (br d, 2 H), 7.28 (d, 1 H), 4.47 (s, 2 H); 
HRMS (ES) m/z calcd for C19H11N6SCl3 ([M+H]
+
) 460.9910, found 460.9915. 
 
 
4-(3-(3-(4-Chlorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)benzonitrile 
(3.59) 
 
A solution of 4-amino-5-(5-(4-chloro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-
thiol (0.0500 g, 0.171 mmol) and 4-cyanophenacyl bromine (0.0383 g, 0.171 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the 
resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers 
were separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 44.9 mg (63%) of 
3.59 as a powder: Mp 272 °C; IR (ATR) 3143, 2919, 2230, 1603, 1290 cm
-1
; 
1
H NMR (400 
MHz, DMSO-d6, 100 °C) δ 13.72 (s, NH 1 H), 8.22 (d, J = 8.4 Hz, 2 H), 8.02 (d, J = 8.8 Hz, 2 
H), 7.86 (d, J = 8 Hz, 2 H), 7.51 (d, J = 8.4 Hz, 2 H), 7.25 (s, 1 H), 4.47 (s, 2 H); 
13
C NMR (100 
MHz, DMSO-d6, 100 °C) δ 141.1, 137.4, 132.3, 128.4, 127.9, 126.7, 117.5, 113.7, 103.0, 22.7, 6 
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quaternary C were missing; HRMS (ES) m/z calcd for C20H12N7SCl ([M+H]
+
) 418.0642, found 
418.0691. 
 
 
3-(3-(4-Chlorophenyl)-1H-pyrazol-5-yl)-6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.60) 
 
A solution of 4-amino-5-(5-(4-chloro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-
thiol (0.0500 g, 0.171 mmol) and 2-chloroacetophenone (0.0264 g, 0.171 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for 90 min. After cooling to rt, the reaction mixture was 
treated with sat. Na2CO3 and the resulting precipitate was filtered, washed with H2O, and dried 
(Na2SO4). Decantation of the residue in dry hexane provided 56.5 mg (84.2%) of 3.60 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.70 (br s, 1 H), 8.06 (br s, 2 H), 7.86 (br s, 2 H), 
7.61 (br s, 3 H), 7.51 (br s, 2 H), 7.27 (s, 1 H), 4.44 (s, 2 H). HRMS (ES) m/z calcd for 
C19H14N6SCl ([M+H]
+
) 393.0684, found 393.0678.  
 
 
6-(2-Chlorophenyl)-3-(3-(4-chlorophenyl)-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.61) 
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A solution of 4-amino-5-(5-(4-chloro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-
thiol (0.0500 g, 0.171 mmol) and 2-bromo-2'-chloroacetophenone (0.0399 g, 0.171 mmol) in 
EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and 
the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The 
layers were separated and the aqueous phase was re-extracted with CH2Cl2. The combined 
organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The 
resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 
46.7 mg (64.0%) of 3.61 as a solid powder: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.66 (br 
s, 1 H), 7.80 (d, J = 8 Hz, 2 H), 7.74 (m, 1 H), 7.65 (d, J = 7.6 Hz, 1H), 7.60 (t, J = 7.4 Hz, 1 H), 
7.55-7.48 (m, 3 H), 7.19 (s, 1 H), 4.31 (s, 2 H); HRMS (ES) m/z calcd for C19H13N6SCl2 
([M+H]
+
) 427.0294, found 427.0287.  
 
 
6-(4-Methoxyphenyl)-7-methyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.64) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol) and 2-bromo-1-(4-methoxyphenyl)propan-1-one (0.109 g, 0.450 
mmol) in EtOH (4 mL) was heated at 95 °C in a microwave for 90 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
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combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 153 mg (93.1%) of 3.64 as a solid: Mp 241 °C; IR (ATR) 3202, 2956, 1560, 1437, 
1260 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.63 (br s, 1 H), 8.00 (ddd, J = 2 Hz, 3.2 
Hz, 8.8 Hz, 2 H), 7.11 (ddd, J = 2 Hz, 3.2 Hz, 8.8 Hz, 2 H), 4.93 (q, J = 7.2 Hz, 1 H), 3.88 (s, 3 
H), 2.84-2.65 (m, 4 H), 2.48-2.43 (m, 2 H), 1.46 (d, J = 8 Hz, 3 H); 
13
C NMR (100 MHz, 
DMSO-d6, 100 °C) δ 162.1, 157.7, 139.2, 128.8, 124.4, 114.3, 31.4, 29.5, 24.6, 23.4, 23.2, 18.7, 
4 quaternary C were missing; HRMS (ES) m/z calcd for C18H19N6SO ([M+H]
+
) 367.1341, found 
367.1348. 
 
 
6-(3,4-Dichlorophenyl)-7-methyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.65) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol) and 2-bromo-1-(3,4-dichlorophenyl)propan-1-one (0.127 g, 0.450 
mmol) in EtOH (4 mL) was heated at 95 °C in a microwave for 60 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 130 mg (71.4%) of 3.65 as a solid: Mp 158 °C; 3279, 2921, 1508, 1454, 1303, 958 cm
-
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1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.70 (br s, 1 H), 8.24 (s, 1 H), 7.98 (d, J = 8.4 Hz, 
1 H), 7.82 (d, J = 8.4 Hz, 1 H), 4.97 (q, J = 7.2 Hz, 1 H), 2.72-2.66 (m, 4 H), 2.43-2.32 (m, 2 H), 
1.48 (d, J = 6.8 Hz, 3 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 155.9, 139.2, 134.3, 132.8, 
131.8, 130.7, 128.8, 127.0, 31.3, 29.5, 23.4, 23.1, 18.5, 4 quaternary C were missing; HRMS 
(ES) m/z calcd for C17H15N6SCl2 ([M+H]
+
) 405.0456, found 405.0465. 
 
 
7-Methyl-6-phenyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.66) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0500 g, 0.225 mmol) and 2-bromopropiophenone (0.0479 g, 0.225 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the 
resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers 
were separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 58 mg (76.6%) of 
3.66 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.65 (br s, 1 H), 8.01 (d, J = 7.2 Hz, 
2 H), 7.62-7.56 (m, 3 H), 4.96 (q, J = 7.2 H, 1 H), 2.78-2.67 (m, 4 H), 2.46 (br s, 2 H), 1.49 (d, J 
= 7.2 Hz, 3 H); HRMS (ES) m/z calcd for C17H17N6S ([M+H]
+
) 337.1230, found 337.1227. 
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6-(4-Chlorophenyl)-7-methyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.67) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol) and 2-bromo-1-(4-chlorophenyl)propan-1-one (0.111 g, 0.450 
mmol) in EtOH (4 mL) was heated at 95 °C in a microwave for 60 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 47.1 mg (28.2%) of 3.67 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.67 (br 
s, 1 H), 8.03 (d, J = 8.4 Hz, 2 H), 7.63 (d, J = 8.4 Hz, 2 H), 4.94 (q, J = 6.8 Hz, 1 H), 2.71 (br s, 4 
H), 2.43 (br s, 2 H), 1.48 (d, J = 6.8 Hz, 3 H); HRMS (ES) m/z calcd for C17H16N6SCl ([M+H]
+
) 
371.0840, found 371.0837.  
 
 
6-(4-Fluorophenyl)-7-methyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.68) 
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A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol) and 2-bromo-1-(4-fluorophenyl)propan-1-one (0.104 g, 0.450 
mmol) in EtOH (4 mL) was heated at 95 °C in a microwave for 60 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 95.6 mg (60%) of 3.68 as a solid: Mp 233 °C; IR (ATR) 3191, 2917, 1500, 1215, 859.2 
cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.66 (br s, 1 H), 8.10 (d, J = 6 Hz, 1 H), 8.08 
(d, J = 6.8 Hz, 1 H), 7.39 (d, J = 8.8 Hz, 1 H), 7.37 (d, J = 8.8 Hz, 1 H), 4.95 (q, J = 7.2 Hz, 1 H), 
2.71 (br s, 1 H), 2.44 (br s, 2 H), 1.48 (d, J = 6.8 Hz, 3 H); 
13
C NMR (100 MHz, DMSO-d6, 100 
°C) δ 165.2, 162.7, 157.1, 139.1, 129.6, 129.5, 128.8, 128.8, 125.4, 115.7, 115.5, 31.5, 29.5, 
23.3, 23.1, 18.5; HRMS (ES) m/z calcd for C17H16N6SF ([M+H]
+
) 355.1141, found 355.1142. 
 
 
7-Methyl-6-phenyl-3-(4,5,6,7-tetrahydro-2H-indazol-3-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.69) 
 
A solution of 4-amino-5-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-4H-(1,2,4)-triazole-3-thiol 
(0.0500 g, 0.212 mmol) and 2-bromopropiophenone (0.0451 g, 0.212 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting 
residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were 
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separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic phases 
were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was 
purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 67.2 mg (90.6%) of 
3.69 as a solid: Mp 160 °C; IR (ATR) 3137, 2924, 1566, 1445, 973 cm
-1
;
 1
H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 12.61 (br s, 1 H), 8.00 (d, J = 7.2 Hz, 2 H), 7.62-7.54 (m, 3 H), 4.96 (q, J = 
7.2 Hz, 1 H), 2.70-2.60 (m, 4 H), 1.85-1.72 (m, 4 H), 1.47 (d, J = 7.2 Hz, 3 H); 
13
C NMR (100 
MHz, DMSO-d6, 100 °C) δ 157.5, 139.1, 132.4, 131.2, 128.5, 126.9, 115.3, 31.3, 22.4, 21.9, 
20.4, 18.5 cm
-1
, 1 aliphatic C and 3 quaternary C were missing; HRMS (ES) m/z calcd for 
C18H19N6S ([M+H]
+
) 351.1392, found 351.1382. 
 
 
3-(3-(4-Fluorophenyl)-1H-pyrazol-5-yl)-7-methyl-6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.70) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 2-bromopropiophenone (0.0386 g, 0.181 mmol) in EtOH (2 mL) 
was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting 
residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were 
separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic phases 
were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was 
purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 66.8 mg (94.5%) of 
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3.70 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 8.08 (d, J = 6.4 Hz, 2 H), 7.90 (d, J = 
5.6 Hz, 1 H), 7.88 (d, J = 5.6 Hz, 1 H), 7.66-7.58 (m, 3 H), 7.29-7.25 (m, 3 H), 5.02 (q, J = 7.2 
Hz, 1 H), 1.50 (d, J = 7.2 Hz, 3 H); HRMS (ES) m/z calcd for C20H16N6SF ([M+H]
+
) 391.1136, 
found 391.1123.  
 
 
3-(3-(4-Fluorophenyl)-1H-pyrazol-5-yl)-6-(4-methoxyphenyl)-7-methyl-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.71) 
 
A solution of 4-amino-5-(5-(4-fluoro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol 
(0.0500 g, 0.181 mmol) and 2-bromo-1-(4-methoxyphenyl)propan-1-one (0.0440 g, 0.181 mmol) 
in EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, 
and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The 
layers were separated and the aqueous phase was re-extracted with CH2Cl2. The combined 
organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The 
resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 
64 mg (84.1%) of 3.71 as a powder: Mp 245 °C; IR (ATR) 3075, 2932, 1603, 1443, 1254 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.61 (br s, 1 H), 8.05-7.89 (m, 4 H), 7.27-7.13 (m, 5 
H), 4.99 (m, 1 H), 3.89 (s, 3 H), 1.48 (d, J = 7.2 Hz, 3 H); 
13
C NMR (100 MHz, DMSO-d6, 100 
°C) δ 162.8, 162.1, 160.4, 157.8, 139.4, 130.6, 128.9, 127.1, 124.3, 115.2, 115.0, 114.3, 102.6, 
55.1, 31.2, 18.9; HRMS (ES) m/z calcd for C21H18N6SFO ([M+H]
+
) 421.1247, found 421.1237. 
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3-(3-(4-Chlorophenyl)-1H-pyrazol-5-yl)-6-(4-methoxyphenyl)-7-methyl-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.72) 
 
A solution of 4-amino-5-(5-(4-chloro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-
thiol (0.0500 g, 0.171 mmol) and 2-bromo-1-(4-methoxyphenyl)propan-1-one (0.0415 g, 0.171 
mmol) in EtOH (2 mL) was heated at 95 °C in a microwave for 90 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 53.9 mg (72.2%) of 3.72 as a powder: Mp 258 °C; IR (ATR) 3070, 2924, 1603, 1439, 
1254, 1027 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 13.68 (br s, 1 H), 8.05 (d, J = 7.2 
Hz, 2 H), 7.87 (br s, 2 H), 7.51 (br s, 2 H), 7.29 (br s, 1 H), 7.14 (d, J = 8 Hz, 2 H), 5.01-5.00 (m, 
1 H), 3.89 (s, 3 H), 1.48 (d, J = 7.2 Hz, 3 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 162.2, 
128.9, 128.3, 126.7, 124.3, 114.4, 102.9, 31.2, 29.9, 18.9, 7 quaternary C were missing; HRMS 
(ES) m/z calcd for C21H18N6SClO ([M+H]
+
) 437.0951, found 437.0954. 
 
N
N
S
N
N
N
NH
Cl
O
  92 
 
3-(3-(4-Chlorophenyl)-1H-pyrazol-5-yl)-7-methyl-6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(3.73) 
 
A solution of 4-amino-5-(5-(4-chloro-phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-
thiol (0.0500 g, 0.171 mmol) and 2-bromopropiophenone (0.0364 g, 0.171 mmol) in EtOH (2 
mL) was heated at 95 °C in a microwave for 90 min. The solvent was evaporated, and the 
resulting residue was dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers 
were separated and the aqueous phase was re-extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 58.2 mg (83.8%) 
of 3.73 as a solid: Mp 246 °C; IR (ATR) 3144, 2924, 1443, 1307, 1087, 954 cm
-1
; 
1
H NMR (400 
MHz, DMSO-d6, 100 °C) δ 13.7 (br s, 1 H), 8.08 (d, J = 6.4 Hz, 2 H), 7.87 (br s, 2 H), 7.64-7.60 
(m, 3 H), 7.51 (br s, 3 H), 7.29 (br s 1 H), 5.02 (q, J = 8 Hz, 1 H), 1.51 (d, J = 7.2 Hz, 3 H); 
13
C 
NMR (100 MHz, DMSO-d6, 100 °C) δ 132.3, 131.4, 128.6, 128.3, 127.0, 126.7, 103.0, 31.44, 
18.77, 7 
13
C peaks were missing; HRMS (ES) m/z calcd for C20H17N6SCl ([M+H]
+
) 407.0846, 
found 407.0837. 
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7-Methyl-6-phenyl-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.74) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0500 g, 
0.194 mmol) and 2-bromopropiophenone (0.0412 g, 0.194 mmol) in EtOH (2 mL) was heated at 
95 °C in a microwave for 90 min. The solvent was evaporated, and the resulting residue was 
dissolved in CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the 
aqueous phase was re-extracted with CH2Cl2. The combined organic phases were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 67 mg (92.9%) of 3.74 as a solid: 
Mp 206 °C; IR (ATR) 3139, 3057, 1607, 1452, 1308, 956 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 8.08 (d, J = 6.4 Hz, 2 H); 7.85 (d, J = 7.2 Hz, 2 H), 7.64-7.59 (m, 3 H), 7.48 (t, J = 7.6 
Hz, 2 H), 7.38 (t, J = 6.8 Hz, 1 H), 7.26 (s, 1 H), 5.02 (q, J = 7.2 Hz, 1 H), 1.51 (d, J = 7.2 Hz, 3 
H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 158.3, 132.3, 131.4, 128.5, 128.4, 127.6, 127.2, 
127.0, 125.0, 102.7, 31.5, 18.8, 3 quaternary 
13
C peaks were missing; HRMS (ES) m/z calcd for 
C20H18N6S ([M+H]
+
) 373.1235, found 373.1252. 
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6,7-Diphenyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.81) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol), desyl chloride (0.104 g, 0.450 mmol) and Et3N (0.130 mL, 0.900 
mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 60 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/ CH2Cl2) and 
provided 75 mg of 3.81 (42.0%) as a solid: Mp 257 °C; IR (ATR) 3247, 2926, 1622, 1445, 951 
cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 7.98 (d, J = 7.2 Hz, 2 H), 7.62-7.53 (m, 3 H), 
7.35-7.27 (m, 5 H), 6.29 (s, 1 H), 2.88-2.73 (m, 4 H), 2.48 (br s, 2 H); 
13
C NMR (100 MHz, 
DMSO-d6, 100 °C) δ 155.8, 146.0, 139.0, 135.5, 133.0, 131.4, 128.7, 128.6, 128.2, 127.0, 126.3, 
125.4, 29.5, 23.5, 23.1, 1 aliphatic C and 2 quaternary C were missing; HRMS (ES) m/z calcd for 
C22H19N6S ([M+H]
+
) 399.1392, found 399.1399. 
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6-(3,4-Dichlorophenyl)-7-isopropyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.82) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.150 g, 0.674 mmol), 2-bromo-1-(3,4-dichlorophenyl)-3-methylbutan-1-one (0.209 g, 
0.674 mmol) and Et3N (0.136 g, 1.35 mmol) in EtOH (5 mL) was stirred at 120 °C in a 
microwave for 60 min. The solvent was evaporated, and the resulting residue was dissolved in 
CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the aqueous 
phase was re-extracted with CH2Cl2. The combined organic phases were washed with brine, 
dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 182 mg (62%) of 3.82 as a solid: 
Mp 150 °C; IR (ATR) 3161, 2958, 1446, 1368, 952 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 
°C) δ 12.75 (s, 1 H), 8.30 (s, 1 H), 8.04 (d, J = 8.4 Hz, 1 H), 7.81 (d, J = 8.4 Hz, 1 H), 4.80 (d, J 
= 7.6 Hz, 1 H), 2.74 (br s, 4 H), 2.46 (br s, 2 H), 1.97 (m, 1 H), 0.93 (d, J = 6.8 Hz, 6 H); 
13
C 
NMR (100 MHz, DMSO-d6, 100 °C) δ 155.2, 139.8, 134.2, 131.8, 130.7, 128.9, 127.2, 125.4, 
42.4, 30.5, 29.6, 23.3, 23.1, 19.2, 18.0, 4 quaternary 
13
C peaks were missing; HRMS (ES) m/z 
calcd for C19H19N6SCl2 ([M+H]
+
) 433.0763, found 433.0752. 
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7-Isopropyl-6-(4-methoxyphenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.83) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0600 g, 0.270 mmol),2-bromo-1-(4-methoxyphenyl)-3-methylbutan-1-one (0.0732 g, 
0.270 mmol) and Et3N (0.0546 g, 0.540 mmol) in EtOH (4 mL) was stirred at 120 °C in a 
microwave for 2 h. The solvent was evaporated, and the resulting residue was dissolved in 
CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the aqueous 
phase was re-extracted with CH2Cl2. The combined organic phases were washed with brine, 
dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 65.2 mg (61%) 3.83 as a solid: Mp 
117 °C; IR (ATR) 3168.6, 2959.8, 1602.9, 1446.4, 1258.1 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 12.66 (br s, 1 H), 8.04 (d, J = 8.8 Hz, 2 H), 7.11 (d, J = 9.2 Hz, 2 H), 4.73-4.70 (m, 1 
H), 3.88 (s, 3 H), 2.77-2.62 (m, 4 H), 2.46 (br m, 2 H), 1.97-1.89 (m, 1 H), 0.95-0.92 (m, 6 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 161.9, 156.8, 139.8, 129.0, 125.7, 125.2, 114.2, 55.1, 
42.6, 30.5, 29.5, 23.3, 23.1, 19.3, 18.1, 3 quaternary 
13
C peaks were missing; HRMS (ES) m/z 
calcd for C20H23N6SO ([M+H]
+
) 395.1649, found 395.1638. 
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7-Isopropyl-6-(4-methoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.84) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0600 g, 
0.232 mmol), 2-bromo-1-(4-methoxyphenyl)-3-methylbutan-1-one (0.0630 g, 0.232 mmol) and 
Et3N (0.0470 g, 0.465 mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 2 h. The 
solvent was evaporated, and the resulting residue was dissolved in CH2Cl2, followed by 
treatment with sat. Na2CO3. The layers were separated and the aqueous phase was re-extracted 
with CH2Cl2. The combined organic phases were washed with brine, dried (Na2SO4), and 
concentrated in vacuo. The resulting residue was purified by chromatography on SiO2 (10% 
MeOH/CH2Cl2) and provided 59.4 mg (59%) of 3.84 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 13.66 (br s, 1 H), 8.09 (d, J = 8.8 Hz, 2 H), 7.86 (d, J = 7.2 Hz, 2 H), 7.49 (t, J = 7.2 
Hz, 2 H), 7.38 (t, J = 7.2 Hz, 1 H), 7.25 (s, 1 H), 7.14 (d, J = 8.8 Hz), 4.78 (d, 7.6 Hz, 1 H), 3.89 
(s, 3 H), 2.00-1.92 (m, 1 H), 0.93 (dd, J = 2.8, 6.8 Hz, 6 H); HRMS (ES) m/z calcd for 
C23H23N6SO ([M+H]
+
) 431.1649, found 431.1638. 
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7-Benzyl-6-(3,4-dichlorophenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.85) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol), 2-bromo-1-(3,4-dichlorophenyl)-3-phenylpropan-1-one (0.161 g, 
0.450 mmol), and Et3N (0.0911 g, 0.900 mmol) in EtOH (4 mL) was stirred at 120 °C in a 
microwave for 1 h. The solvent was evaporated, and the resulting residue was dissolved in 
CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the aqueous 
phase was re-extracted with CH2Cl2. The combined organic phases were washed with brine, 
dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 140 mg (64%) of 3.85 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.71 (br s, 1 H), 8.01 (s, 1 H), 7.85 (d, J = 6.8 Hz, 1 
H), 7.70 (d, J = 8.4, 1 H), 7.23-7.16 (m, 5 H), 5.18 (t, J = 7.2 Hz, 1 H), 3.08-3.01 (m, 3 H), 2.75 
(br s, 4 H), 2.47 (br s, 2 H); HRMS (ES) m/z calcd for C23H19N6SCl2 ([M+H]
+
) 481.0763, found 
481.0754. 
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7-Benzyl-6-(4-methoxyphenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.86) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.0600 g, 0.270 mmol), 2-bromo-1-(4-methoxyphenyl)-3-phenylpropan-1-one (0.0862 g, 
0.270 mmol), and Et3N (0.0546 g, 0.540 mmol) in EtOH (4 mL) was stirred at 120 °C in a 
microwave for 1 h. The solvent was evaporated, and the resulting residue was dissolved in 
CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the aqueous 
phase was re-extracted with CH2Cl2. The combined organic phases were washed with brine, 
dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/ CH2Cl2) and provided 98.1 mg (82%) 3.86 as a solid: 
1
H 
NMR (400 MHz, DMSO-d6, 100 °C) δ 12.62 (br s, 1 H), 7.90 (d, J = 8.8 Hz, 2 H), 7.24-7.17 (m, 
5 H), 7.04 (d, J = 8.8 Hz, 2 H), 5.10 (t, J = 6.8 Hz, 3 H), 3.08 (dd, J = 6 Hz, 14 Hz, 2 H), 2.87-
2.72 (m, 4 H), 2.47 (br s, 2 H); HRMS (ES) m/z calcd for C24H23N6SO ([M+H]
+
) 433.1649, 
found 433.1637. 
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7-Benzyl-6-(3,4-dichlorophenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.87) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.100 g, 
0.387 mmol), 2-bromo-1-(3,4-dichlorophenyl)-3-phenylpropan-1-one (0.139 g, 0.387 mmol), 
and Et3N (0.0784 g, 0.774 mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 1 h. 
The solvent was evaporated, and the resulting residue was dissolved in CH2Cl2, followed by 
treatment with sat. Na2CO3. The layers were separated and the aqueous phase was re-extracted 
with CH2Cl2. The combined organic phases were washed with brine, dried (Na2SO4), and 
concentrated in vacuo. The resulting residue was purified by chromatography on SiO2 (10% 
MeOH/CH2Cl2) and provided 176 mg (88%) of 3.87 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 13.68 (br s, 1 H), 8.08 (br s, 1 H), 7.88 (br s, 3 H), 7.75 (br s, 1 H), 7.50 (t, J = 6.4 Hz, 
2 H), 7.41-7.38 (m, 1 H), 7.22-7.13 (m, 6 H), 5.25 (t, J = 7.2 Hz, 1 H), 3.12-3.01 (m, 2 H); 
HRMS (ES) m/z calcd for C26H19N6SCl2 ([M+H]
+
) 517.0763, found 517.0747. 
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7-Benzyl-6-(4-methoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.88) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0600 g, 
0.232 mmol), 2-bromo-1-(4-methoxyphenyl)-3-phenylpropan-1-one (0.0741 g, 0.232 mmol), and 
Et3N (0.0470 g, 0.465 mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 1 h. The 
solvent was evaporated, and the resulting residue was dissolved in CH2Cl2, followed by 
treatment with sat. Na2CO3. The layers were separated and the aqueous phase was re-extracted 
with CH2Cl2. The combined organic phases were washed with brine, dried (Na2SO4), and 
concentrated in vacuo. The resulting residue was purified by chromatography on SiO2 (10% 
MeOH/CH2Cl2) and provided 104 mg (94%) of 3.88 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 13.58 (br s, 1 H), 7.97 (d, J = 8.4 Hz, 2 H), 7.86 (d, J = 7.6 Hz, 2 H), 7.49 (t, J = 7.2 
Hz, 2 H), 7.39 (t, J = 7.2 Hz, 1 H), 7.23-7.14 (m, 6 H), 7.07 (d, J = 8.4 Hz, 2 H), 5.17 (t, J = 7.2 
Hz, 1 H), 3.10-3.05 (m, 2 H); HRMS (ES) m/z calcd for C27H23N6SO ([M+H]
+
) 479.1649, found 
479.1633. 
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6-(3,4-Dichlorophenyl)-7-iso-butyl-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.89) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.0800 g, 
0.310 mmol),2-bromo-1-(3,4-dichlorophenyl)-4-methylpentan-1-one(0.100 g, 0.310 mmol), and 
Et3N (0.0627 g, 0.619 mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 1 h. The 
solvent was evaporated, and the resulting residue was dissolved in CH2Cl2, followed by 
treatment with sat. Na2CO3. The layers were separated and the aqueous phase was re-extracted 
with CH2Cl2. The combined organic phases were washed with brine, dried (Na2SO4), and 
concentrated in vacuo. The resulting residue was purified by chromatography on SiO2 (10% 
MeOH/CH2Cl2) and provided 121 mg (81%) of 3.89 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ 13.67 (br s, 1 H), 8.29 (s, 1 H), 8.03 (d, J = 8.4 Hz, 1 H), 7.86 (d, J = 8.4 Hz, 3 H), 
7.48-7.26 (m, 4 H), 4.95 (q, J = 6 Hz, 1 H), 1.91-1.81 (m, 1 H), 1.61-1.49 (m, 2 H); HRMS (ES) 
m/z calcd for C23H21N6SCl2 ([M+H]
+
) 483.0920, found 483.0908. 
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7-iso-Butyl-6-(4-methoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.90) 
 
A solution of 4-amino-5-(5-phenyl-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.100 g, 
0.387 mmol), 2-bromo-1-(4-methoxyphenyl)-4-methylpentan-1-one (0.110 g, 0.387 mmol), and 
Et3N (0.0784 g, 0.774 mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 1 hour. 
The solvent was evaporated, and the resulting residue was dissolved in CH2Cl2, followed by 
treatment with sat. Na2CO3. The layers were separated and the aqueous phase was re-extracted 
with CH2Cl2. The combined organic phases were washed with brine, dried (Na2SO4), and 
concentrated in vacuo. The resulting residue was purified by chromatography on SiO2 (10% 
MeOH/CH2Cl2) and provided 150 mg (87%) of 3.90 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 
100 °C) δ13.63 (br s, 1 H), 8.06 (d, J = 8.4 Hz, 2 H), 7.86-7.83 (m, 2 H), 7.51-7.49 (m, 2 H), 
7.40 (d, J = 6.4 Hz, 1 H), 7.26 (br s, 1 H), 7.17 (d, J = 8.4 Hz, 1 H), 7.06 (d, J = 8.4 Hz, 2 H), 
4.91 (q, J = 5.2 Hz, 1 H), 3.90 (s, 3 H), 1.92-1.84 (m, 1 H), 1.61-1.49 (m, 2 H); HRMS (ES) m/z 
calcd for C24H25N6SO ([M+H]
+
) 445.1805, found 445.1793. 
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6-(3,4-Dichlorophenyl)-7-iso-butyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.91) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol), 2-bromo-1-(3,4-dichlorophenyl)-4-methylpentan-1-one (0.146 g, 
0.450 mmol), and Et3N (0.0911 g, 0.900 mmol) in EtOH (4 mL) was stirred at 120 °C in a 
microwave for 1 h. The solvent was evaporated, and the resulting residue was dissolved in 
CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the aqueous 
phase was re-extracted with CH2Cl2. The combined organic phases were washed with brine, 
dried (Na2SO4), and concentrated in vacuo. The resulting residue was purified by 
chromatography on SiO2 (10% MeOH/CH2Cl2) and provided 133 mg (66%) of 3.91 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.71 (br s, 1 H), 8.24 (s, 1 H), 7.98 (dd, J = 2 Hz, 8.4 
Hz, 1 H), 7.83 (d, J = 8.8 Hz, 1 H), 4.90 (t, J = 7.6 Hz, 1 H), 2.73 (br s, 4 H), 2.47 (br s, 2 H), 
1.89-1.79 (m, 1 H), 1.55-1.52 (m, 2 H); HRMS (ES) m/z calcd for C20H21N6SCl2 ([M+H]
+
) 
447.0920, found 447.0911. 
 
 
7-iso-Butyl-6-(4-methoxyphenyl)-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.92) 
N
N
S
N
N
N
NH
Cl
Cl
  105 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.100 g, 0.450 mmol), 2-bromo-1-(4-methoxyphenyl)-4-methylpentan-1-one (0.128 g, 
0.450 mmol), and Et3N (0.0911 g, 0.900 mmol) in EtOH (4 mL) was stirred at 120 °C in a 
microwave for 1 hour. The solvent was evaporated, and the resulting residue was dissolved in 
CH2Cl2, followed by treatment with sat. Na2CO3. The layers were separated and the aqueous 
phase was re-extracted with CH2Cl2. The combine organic phases were washed with brine, dried 
(Na2SO4), and concentrated in vacuo. The resulting residue was purified by chromatography on 
SiO2 (10% MeOH/CH2Cl2) and provided 120 mg (65%) of 3.92 as a solid: 
1
H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 12.65 (br s, 1 H), 8.03-7.97 (m, 2 H), 7.14-7.03 (m, 2 H), 4.85 (t, J = 6.4 
Hz, 1 H), 3.88 (s, 3 H), 2.72 (br s, 4 H), 2.44 (br s, 2 H), 1.89-1.80 (m, 1 H), 1.53-1.51 (m, 2 H), 
0.96-0.93 (m, 6 H); HRMS (ES) m/z calcd for C21H25N6SO ([M+H]
+
) 409.1805, found 409.1796. 
 
 
7,7-Dimethyl-6-phenyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.75) 
 
A solution of 2-bromoisobutyrophenone (0.100 g, 0.440 mmol), 4-Amino-5-(1,4,5,6-
tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-3-thiol (0.300 g, 1.32 mmol) and Et3N 
(0.223 g, 2.20 mmol) in EtOH (5 mL) was stirred at 80 °C for 8 h and then concentrated under 
reduced pressure. The residue was diluted with sat. NaHCO3 solution and extracted with EtOAc. 
The organic layer was dried over Na2SO4 and concentrated under reduced pressure, the resulting 
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residue was purified by column chromatography on SiO2 with EtOAc/MeOH (20:1) to give 63 
mg (41%) of 3.75 as a solid: 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.62 (br s, 1 H), 7.58-
7.51 (m, 5 H), 2.66-2.58 (m, 4 H), 2.34-2.33 (m, 2 H), 1.61 (s, 6 H); HRMS (ES) m/z calcd for 
C18H19N6S ([M+H]
+
) 351.1386, found 351.1379. 
 
 
6-(3,4-Dichlorophenyl)-7,7-dimethyl-3-(2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.80) 
 
A solution of 4-amino-5-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-4H-(1,2,4)-triazole-
3-thiol (0.139 g, 0.623 mmol), 2-bromo-1-(3,4-dichlorophenyl)propan-1-one (0.221 g, 0.748 
mmol), and Et3N (0.189 g, 1.87 mmol) in EtOH (4 mL) was heated at 95 °C in a microwave for a 
total of 90 min. After cooling to rt, the reaction mixture was treated with sat. Na2CO3 and the 
resulting precipitate was filtered, washed with H2O, and dried (Na2SO4). Decantation of the 
residue in dry hexane provided 174 mg (66.7%) of 3.80 as a solid: Mp 232 °C; IR (ATR) 3098, 
2900, 1681, 1452, 1031, 816 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.63 (br s, 1 H), 
7.86 (s, 1 H), 7.75 (d, J = 8.4 Hz, 1 H), 7.60 (d, J = 7.6 Hz, 1 H), 2.64-2.61 (m, 4 H), 2.37 (br s, 2 
H), 1.63 (s, 6 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 161.2, 141.0, 133.7, 132.9, 131.1, 
130.1, 130.0, 128.2, 42.6, 25.9, 23.6, 1 aliphatic C and 5 quaternary C were missing; HRMS (ES) 
m/z calcd for C18H17N6SCl2 ([M+H]
+
) 419.0612, found 419.0630. 
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3-(3-(4-Chlorophenyl)-1H-pyrazol-5-yl)-7,7-dimethyl-6-phenyl-7H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazine (3.76) 
 
A solution of 2-bromoisobutyrophenone (0.233 g, 1.02 mmol), 4-amino-5-(5-(4-chloro-
phenyl)-2H-pyrazol-3-yl)-4H-(1,2,4)triazole-3-thiol (0.100 g, 0.342 mmol) and Et3N (0.143 mL, 
1.02 mmol) in EtOH (4 mL) was stirred at 95 °C in a microwave for a total of 90 min. After 
cooling to rt, the reaction mixture was treated with sat. Na2CO3 and the resulting precipitate was 
filtered, washed with H2O, and dried (Na2SO4). Decantation of the residue in dry hexane 
provided 90 mg (62.9%) of 3.76 as a solid: Mp 275 °C; IR (ATR) 3150, 3027, 1582, 1452, 1195, 
805 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.64 (br s, 1 H); 7.77 (d, J = 6.8 Hz, 2 H), 
7.62-7.48 (m, 7 H), 7.13 (s, 1 H), 1.64 (s, 6 H); 
13
C NMR (100 MHz, DMSO-d6, 100 °C) δ 
163.9, 141.6, 133.4, 132.3, 129.6, 128.3, 127.9, 126.6, 102.9, 42.7, 26.2, 6 quaternary C were 
missing; HRMS (ES) m/z calcd for C21H18N6SCl ([M+H]
+
) 421.1002, found 421.1016. 
 
 
6-(4-Methoxyphenyl)-7-methyl-3-propyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.100) 
 
A solution of 4-amino-5-propyl-4H-[1,2,4]triazole-3-thiol (0.0600 g, 0.379 mmol), 2-
bromo-1-(4-methoxyphenyl)propan-1-one (0.0922 g, 0.379 mmol), and Et3N (0.0767 g, 0.758 
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mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 1 h. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 89.4 mg (78%) of 3.100 as a solid: Mp 135 °C; IR (ATR) 3059, 2956, 1605, 1458, 
1184, 988 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6) δ 8.00 (d, J = 8.8 Hz, 2 H), 7.13 (d, J = 8.8 Hz, 
2 H), 5.00 (q, J = 7.2 Hz, 1 H), 3.85 (s, 3 H), 2.91-2.86 (m, 2 H), 1.80-1.70 (m, 2 H), 1.34 (d, J = 
7.2 Hz, 3 H), 0.94 (t, J = 7.6 Hz, 3 H); 
13
C NMR (125 MHz, DMSO-d6) 162.3, 157.1, 153.0, 
138.4, 129.1, 124.6, 114.7, 55.6, 31.4, 25.8, 20.0, 19.4, 13.5; HRMS (ES) m/z calcd for 
C15H19N4SO ([M+H]
+
) 303.1280, found 303.1268. 
 
 
3-Benzyl-6-(4-methoxyphenyl)-7-methyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.101) 
 
A solution of 4-amino-5-benzyl-4H-1,2,4-triazole-3-thiol (0.0600 g, 0.291 mmol), 2-
bromo-1-(4-methoxyphenyl)propan-1-one (0.0707 g, 0.291 mmol), and Et3N (0.0589 g, 0.582 
mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 2 h. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
N
N
S
N
N
O
  109 
provided 67.8 mg (67%) of 3.101 as a solid: 
1
H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 8.8 
Hz, 2 H), 7.33-7.20 (m, 5 H), 7.11 (d, J = 8.8 Hz, 2 H), 4.99 (q, J = 7.2 Hz, 1 H), 4.32 (s, 2 H), 
3.85 (s, 3 H), 1.26 (d, J = 7.2 Hz, 3 H); HRMS (ES) m/z calcd for C19H19N4SO ([M+H]
+
) 
351.1274, found 351.1263. 
 
 
3-Isopropyl-6-(4-methoxyphenyl)-7-methyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.102) 
 
A solution of 4-amino-5-(propan-2-yl)-4H-1,2,4-triazole-3-thiol  (0.0600 g, 0.379 mmol), 
2-bromo-1-(4-methoxyphenyl)propan-1-one (0.0922 g, 0.379 mmol), and Et3N (0.0767g, 0.758 
mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 2 h. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 97.1 mg (85%) of 3.102 as a solid: Mp 141 °C; IR (ATR) 3061, 2965, 1607, 1456, 
1185, 988 cm
-1
; 
1
H NMR (500 MHz, DMSO-d6) δ 8.00 (ddd, J = 2.4 Hz, 4.4 Hz, 8 Hz, 2 H), 
7.14 (ddd, J = 2.4 Hz, 4 Hz, 8 Hz, 2 H), 5.00 (q, J = 6 Hz, 1 H), 3.86 (s, 3 H), 3.38-3.34 (m, 1 H), 
1.39 (d, J = 5.6 Hz, 3 H), 1.35 (d, J = 5.6 Hz, 3 H), 1.31 (d, J = 5.6 Hz, 3 H); HRMS (ES) m/z 
calcd for C15H19N4SO ([M+H]
+
) 303.1280, found 303.1285. 
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6-(4-Methoxyphenyl)-7-methyl-3-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.103) 
 
A solution of 4-amino-5-phenyl-4H-1,2,4-triazole-2-thiol (0.100 g, 0.520 mmol), 2-
bromo-1-(4-methoxyphenyl)propan-1-one (0.126 g, 0.520 mmol), and Et3N (0.105 g, 1.04 
mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 90 min. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 141 mg (81%) of 3.103 as a solid: 
1
H NMR (300 MHz, DMSO-d6) δ 8.20-7.97 (m, 4 
H), 7.61-7.56 (m, 3 H), 7.13 (d, J = 8.7 Hz, 2 H), 5.04 (q, J = 7.2 Hz, 1 H), 3.85 (s, 3 H), 1.44 (d, 
J = 7.2 Hz, 3 H); HRMS (ES) m/z calcd for C18H17N4SO ([M+H]
+
) 337.1118, found 337.1110. 
 
 
3-Benzyl-6-(3,4-dichlorophenyl)-7-methyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (3.104) 
 
A solution of 4-amino-5-benzyl-4H-1,2,4-triazole-3-thiol (0.0800 g, 0.388 mmol), 2-
bromo-1-(3,4-dichlorophenyl)propan-1-one (0.109 g, 0.388 mmol), and Et3N (0.0785 g, 0.776 
mmol) in EtOH (4 mL) was stirred at 120 °C in a microwave for 2 h. The solvent was 
evaporated, and the resulting residue was dissolved in CH2Cl2, followed by treatment with sat. 
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Na2CO3. The layers were separated and the aqueous phase was re-extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried (Na2SO4), and concentrated in vacuo. 
The resulting residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) and 
provided 137 mg (91%) of 3.104 as a solid: 
1
H NMR (500 MHz, DMSO-d6) δ 7.95 (s, 1 H), 7.94 
(d, J = 2 Hz, 1 H), 7.85 (d, J = 8.5 Hz, 1 H), 7.33-7.21 (m, 5 H), 5.00 (q, J = 7 Hz, 1 H), 4.35 (d, 
J = 2.5 Hz, 2 H), 1.28 (d, J = 7 Hz, 3 H); HRMS (ES) m/z calcd for C18H15N4SCl2 ([M+H]
+
) 
389.0389, found 389.0377. 
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APPENDIX B 
KINASE INHIBITION BY 669 
 
% of 
DMSO 
Control 
Kinase 
Activity 
 
% of 
DMSO 
Control 
Kinase 
Activity 
 
% of 
DMSO 
Control 
Kinase 
Activity 
Kinase 
669 @ 9 
μM 
Kinase 
669 @ 9 
μM 
Kinase 
669 @ 9 
μM 
Ab1(h) 106 FGFR1(h) 97 PKCη(h) 101 
Ab1(T315I)(h) 107 FGFR2(h) 92 PKCθ(h) 83 
Arg(h) 103 FGFR3(h) 91 PKCι(h) 105 
Aurora-A(h) 97 FGFR4(h) 86 PKCμ(h) 93 
Ax1(h) 108 Lck(h) 104 PKD2(h) 104 
Bmx(h) 91 Lyn(h) 87 PRAK(h) 89 
BTK(h) 95 MAPK1(h) 103 PRK2(h) 117 
CaMKIIβ(h) 80 MAPK2(h) 113 Pyk2(h) 108 
CaMKIV(h) 89 MEK1(h) 101 F1t1(h) 92 
CDK1/cyclinB(h) 113 Met(h) 100 F1t3(h) 81 
  156 
CDK2/cyclinA(h) 118 MST2(h) 98 F1t4(h) 96 
CDK2/cyclinE(h) 89 NEK2(h) 113 Fms(h) 92 
CDK3/cyclinE(h) 88 p70S6K(h) 82 Fyn(h) 108 
CDK5/p35(h) 99 PAK2(h) 107 GSK3β(h) 65 
CDK6/cyclinD3(h) 108 PAR-1Bα(h) 104 1GF-1R(h) 107 
CDK7/cyclinH/MAT1(h) 104 PDGFRα(h) 112 JAK2(h) 123 
CHK1(h) 96 PDGFRβ(h) 90 JAK3(h) 82 
CHK2(h) 93 PDK1(h) 90 Ret(h) 106 
CK1(y) 93 PKA(h) 90 Ros(h) 105 
CK1δ(h) 84 PKBα(h) 92 Rsk1(h) 88 
CK2(h) 107 PKBβ(h) 86 Rsk1® 70 
cKit(h) 102 PKBγ(h) 77 Rsk2(h) 88 
c-RAF(h) 96 PKCα(h) 104 Rsk3(h) 79 
CSK(h) 100 PKCβII(h) 103 SGK(h) 70 
cSRC(h) 110 PKCγ(h) 97 Syk(h) 84 
EGFR(h) 95 PKCδ(h) 109 Tie2(h) 75 
EphB2(h) 136 PKCε(h) 111 Yes(h) 81 
EphB4(h) 102 PKCζ(h) 97   
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APPENDIX C 
ADME STUDY OF LEAD COMPOUND 669 
Compd 
Test 
conc 
(mM) 
Test 
species 
NADPH-
dependent 
CLint
a 
(ml 
min
-1
mg
-1 
NADPH-
dependent 
T1/2
b 
(min) 
NADPH-
free CLint
a  
(mlmin-
1
mg
-1
 
NADPH-
free T1/2
b 
(min) 
Comment 
Verapamil 
1.0 Human 274 8.4 6.2 374 
High-
metabolized 
control 
1.0 Mouse 336 6.9 0 > 200 
Warfarin 
1.0 Human  0.4 > 180 0 > 180 
High-
metabolized 
control 
1.0 Mouse 5 > 180 0 > 180 
669 
1.0 Human 166 14.0 2.5 928 
 
1.0 Mouse 521 4.4 31.1 74 
a
Microsomal Intrinsic Clearance 
b
Half-life 
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APPENDIX D 
METABOLITE IDENTIFICATION OF 669 IN MOUSE MICROSOMES 
Compd Mass Retention 
time (min) 
MW 
difference 
Possible 
metabolic 
pathway 
Product 
Ion mass 
Comment 
669 390 3.4 - - 133,161 Parent 
319 2.9, 3.1 - 71    
347 3.2 - 43    
361 3.2 - 29    
385 2.8 - 5    
406 2.9 + 16 hydroxylation   
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